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Abstract 
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective 
therapeutic option for many malignant diseases. However, the efficacy of allo-HSCT is limited 
by the occurrence of destructive graft-versus-host disease (GVHD). Since allogeneic T cells are 
the driving force in the development of GVHD, their activation, proliferation, and differentiation 
are key factors to understanding GVHD pathogenesis. On the other hand, antigen-presenting 
cells (APCs) are essential for allogeneic T-cell priming and the development of GVHD. The T-
box transcription factor T-bet is a master regulator for IFN-γ production and Th1 differentiation. 
T-bet also regulates the functions of APCs including dendritic cells (DCs) and B cells. Therefore, 
we investigated the role of T-bet in T cell responses, as well as on APC functions, in acute 
GVHD (aGVHD) using murine models of allogenic bone marrow transplantation (allo-BMT). 
In Chapter 2, we evaluated the roles of T-bet and IFN-γ in T-cell responses. T-bet-/- T 
cells induced significantly less GVHD compared with either wild-type (WT) or IFN-γ-/- 
counterparts in CD4-driven major histocompatibility complex (MHC)- or minor 
histocompatibility antigen (miHA)–mismatched models. We defined several T-bet-dependent but 
IFN-γ-independent molecules that may account for this distinct outcome. Further study indicates 
that T-bet also controls the optimal activity of Th17 cells to induce GVHD. Moreover, the 
compromised graft-versus-leukemia (GVL) effect of T-bet-/- T cells could be essentially reversed 
by IL-17 neutralization. Thus, targeting T-bet or regulating its downstream effectors independent 
of IFN-γ may be a promising strategy to control GVHD in the clinic. 
 ix 
 
In Chapter 3, we evaluated the role of T-bet on APCs and found that T-bet-/- recipients 
developed much milder GVHD than their WT counterparts in MHC-mismatched or CD4-
depedent miHA-mismatched models. As the functional readout of APCs, allogeneic donor T 
cells, particular CD4 subpopulation, significantly reduced IFN-γ production, proliferation and 
migration, and caused less damage in liver and gut in T-bet-/- recipients. We further observed that 
T-bet on recipient hematopoietic APCs, particular DCs, was primarily responsible for donor T-
cell response and pathogenicity in GVHD. In fact, Trail/DR5 interaction served as a major 
signaling pathway responsible for donor T-cell apoptosis and impaired GVHD development in 
T-bet-/- recipients.  Furthermore, T-bet expression on the host is largely dispensable for the GVL 
effect.  
Taken together, we propose that T-bet is a potential therapeutic target for the control of 
GVHD through regulating T cells as well as APCs.  We believe further exploration and 
understanding of the immunobiology of T-bet in controlling the activities of T cells and APCs in 
GVHD will expand therapeutic options for the continuing success of allo-HSCT. 
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Chapter 1: Background1 
 
1.1 T-bet: a master regulator shaping immune responses 
            T-bet is a T-box family transcription factor encoded by Tbx21, which denotes “T-box 
expressed in T cells” due to its original discovery in controlling the activity and function of T 
helper type 1 (Th1) cells (1). While accumulating studies have shown that T-bet is expressed in 
multiple immune cell lineages, including dendritic cells (DCs), natural killer (NK) cells, NKT 
cells, and certain subsets of innate lymphoid cells (ILCs) in the innate immune system, as well as 
CD4 and CD8 T cells, B cells, and γδ T cells in the adaptive immune system. Thus, T-bet serves 
as a master regulator to shape immune responses and has been considered as a bridge to link 
innate and adaptive immunity (2). 
 
1.1.1 T-bet in innate immunity 
            The innate immune system provides the first line defense against infection. As one of the 
major professional antigen presenting cells (APCs) in the innate immune system, DCs always 
attract the attention of researchers.  Shortly after T-bet was defined in Th1 cells (1), a different 
study demonstrated that the expression of T-bet in human myeloid DCs could be induced rapidly 
and directly by IFN-γ (3). The adjuvant activity of CpG DNA to control infection also requires 
T-bet expression in murine DCs (4). Functional studies both in vitro and in vivo further indicated 
                                                      
1
 Portions of this chapter have been previously published (Fu et al. Arch Immunol Ther Exp 
(Warsz). 2014 Aug; 62(4):277-301.) and are utilized with permission of the publisher (p130). 
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that T-bet is crucial for optimal IFN-γ production by DCs, and is required for antigen-specific 
CD4 T-cell priming (5). Mechanistically, several signaling pathways have been identified 
responsible for T-bet expression in DCs, including IFN-γ, IL-12, IL-18 and Toll-like receptor 9 
(TLR9), among which the IFN-γ signaling seems to be the dominate pathway (4, 6, 7). Upon 
interacting with T-cell receptor (TCR) on T cells, the DCs will produce IFN-γ and IL-12, which 
then triggers T-bet-driven Th1 differentiation from naïve CD4 T cells (6). On the other hand, 
overexpression of T-bet in DCs can enhance the surface expression of CXCR3 and IL-12Rβ2 on 
CD4 T cells, and promote the granzyme B and IFN-γ production by CD8 T cells resulting in the 
augmented tumor antigen specific CD8 T-cell responses (7). Therefore, the potential positive 
feedback loop constituted by IFN-γ and T-bet in DCs play an important role to activate T cells, 
connecting the innate and adaptive immune responses.  
            NK cells are able to rapidly respond to viral infection and tumors, because they kill the 
target cells without recognizing MHC or producing antibodies. NKT cells are considered as a 
heterogeneous group of T cells sharing the characteristics of T cells and NK cells, thus involving 
both innate and adaptive immunity. The expression of T-bet is required for the development, 
maturation, and function of both NK and NKT cells (8-10). T-bet-/- NK cells are immature and 
sensitive towards apoptosis (8). Subsequent study revealed that the normal development and 
terminal maturation of NK cells relies on the combination regulation of both T-bet and another 
T-box transcription factor eomesodermin (Eomes) (9). The failure of IFN-γ production and 
impaired survival of T-bet-/- NKT cells are possibly due to the low response to IL-15 receptor 
signaling given the decreased expression of CD122 (IL-2 and IL-15 receptor β-subunit) (8). 
However, despite of reduction in number, T-bet-/- NKT cells, are sufficient to induce the airway 
hyperreactivity through the compensatory increase of IL-4 and IL-13 (11). 
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             T-bet has also been shown to play a critical role to control the development and proper 
function of ILCs, a family of cells regulating homeostasis and remodeling at mucosal sites, 
particular group 1 and 3 with the dominate expression of transcription factor T-bet and RORγt, 
respectively (12). T-bet+ ILC1s are responsive to IL-12 and IL-15, and can produce IFN-γ (13), 
which was found to correlate with mucosal tissue inflammation in human Crohn’s disease (14). 
The plasticity of ILC3s seems to be controlled by T-bet. T-bet expression in ILC3s leads to the 
induction of IFN-γ and repression of IL-17 that is partially mediated through IL-7 receptor 
signaling (15). The expression of T-bet was then identified in CCR6-, not CCR6+ ILC3 subsets, 
which is positively related to the natural cytotoxicity receptor NKp46 expression and IFN-γ 
production that is essential for protecting epithelial barrier against infection (16). 
 
1.1.2 T-bet in adaptive immunity 
            The adaptive immune system consists of multiple highly specialized cells to eliminate 
pathogens. The clonal expansion of T lymphocytes is initiated through TCR recognition of 
specific pathogen-derived antigens presented by APCs. Unlike in the innate immune system, 
effect of T-bet in the adaptive immune system has been extensively studied especially in CD4 
and CD8 T cells (2).  
             Although naïve CD4 T cells do not express T-bet, it is actively induced through the 
stimulation of TCR and IFN-γR signaling as the first wave, and IL-12R signaling as the second 
wave (1, 17-19). T-bet self-induction did not occur when IFN-γ or IL-12 was present during Th1 
differentiation, but this may happen through IFN-γ and IL-12-independent pathways (20). The 
regulation of T-bet expression in Th1 cells also occurs at post-transcriptional or post-
 4 
 
translational levels controlled by the microRNA-29 (21, 22) or the ubiquitin-dependent 
degradation pathway which involves the Lys-313 in the T-box domain (23), respectively. 
            T-bet has a unique role in the differentiation of all three subsets (Th1, Th2, Th17) of 
CD4+ Th cells by promoting the Th1 differentiation, while simultaneously inhibiting the 
opposing Th2 and Th17 lineage commitment (24). This involves a complex epigenetic regulation 
network (25). The bivalent histone H3 lysine 4 (H3K4me3) and H3K27me3 modifications reveal 
the flexibility of master regulator expression in different lineages, particularly for the murine 
Tbx21 locus (26). T-bet associates with RbBp5, a core component of H3K4 methyltransferase 
complexes, and with JMJD3, a H3K27 demethylase (27). Epigenetic studies showed that T-bet is 
able to mediate the removal of the repressive H3K27me3 mark at the Ifng and Cxcr3 promoters 
and establish the permissive H3K4-methylation state in mice (27).  The concomitant repression 
or interference of other lineage-specific transcription factors, on the other hand, helps the 
reinforcement of Th1 differentiation. For example, T-bet directly binds to Gata3 locus (28), or 
indirectly binds to Il4 silencer site by forming a T-bet-RUNX3 complex (29), effectively 
preventing Th2 differentiation. Similarly, T-bet binds to RORγt activator RUNX1 that prevents 
Rorc (which encodes RORγt) and Il17 expression and impairs Th17 differentiation (30). 
            While T-bet predominately controls the production of IFN-γ by CD4 T cells (31), it has 
cooperative and partially redundant function with Eomes in regulating homeostasis and cytolytic 
activity of CD8 T cells (32-34).  T-bet expression in CD8 T cells also relies on TCR and IL-12R 
signaling, which accounts for the early activation of antigen-specific CD8 T cells. Then Eomes is 
induced in a RUNX3-dependent manner, and substitutes T-bet to further produce IFN-γ and 
granzyme B (35, 36). Once the pathogen clearance is achieved, a reservoir of memory CD8 T 
cells is generated. T-bet expression is associated with effector memory T cells that are equipped 
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with a more differentiated phenotype (37), while Eomes is more important for the maintenance 
of central memory cells (38). 
            B cells can produce different antibodies in response to antigen stimulation, through a 
process that includes affinity maturation and class-switch recombination. Studies show that T-bet 
can regulate IgG class switching in B cells and thus control their autoantibody production (39). 
IFN- γ, TLR9 and CD40 signaling induces T-bet expression in B cells, and leads to subsequent 
induction of IgG2a, IgG2b and IgG3, but repression of IgG1and IgE (39-41). T-bet also regulates 
the persistence and survival of IgG2a+CD38hi memory B cells through transcriptional regulation 
of mature B cell receptor (42). Moreover, the migration of IgG2a+ memory B cells to 
inflammatory sites is driven by T-bet through positively controlling chemokine receptor CXCR3 
(43) .  
            T-bet is inducibly expressed in γδ T cells, a subset of the non-conventional T cells, 
through TCR signaling (44). The cytokine production of γδ T cells, particularly IFN-γ, is 
regulated by both T-bet and Eomes (45). 
 
1.1.3 T-bet in disease  
            Given T-bet regulates various cell types in both innate and adaptive immune systems, it is 
not surprising that T-bet plays a critical role in many diseases, which have been summarized in 
Table 1.1.  The effect of T-bet could be either beneficial or detrimental, depending on the types 
of cells that are controlled by T-bet, and how they contribute to the pathogenesis of different 
diseases. Graft-versus-host disease (GVHD), which occurrs after the allogeneic hematopoietic 
stem cell transplantation (allo-HSCT), is our absolute focus in this dissertation. 
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Table 1.1 Role of T-bet in regulating different diseases.  
 
Disease Role of  
T-bet 
Cell 
Type 
Affected 
Evidence Refs 
GVHD detrimental CD4 T, 
CD8 T; 
APCs 
- Control T-cell differentiation and function 
through IFN-γ-independent manners; 
- Regulate hematopoietic APC function to 
promote allogeneic T-cell proliferation, 
migration, and survival.  
(46) 
(47) 
 
(48) 
Experimental 
autoimmune 
encephalomy
elitis (EAE)  
detrimental 
 
 
 
dispensable 
 
 
Th1 and 
Th17 
 
 
Th17 
- T-bet-dependent pathway, such as IL-23R 
signaling, but not pathway-specific end 
products, such as IFN-γ and IL-17, contributes 
to CD4 T-cell encephalitogenicity. 
- T-bet-/- Th17 cells maintain/enhance GM-CSF 
and IL-17 production, and are able to induce 
EAE.  
(49) 
(50) 
(51) 
 
(52) 
(53) 
Crohn's 
disease 
detrimental 
 
Th1 
 
 
ILC1s 
- Increased T-bet expression and IFN-
γ production in CD4+ T cells correlates with 
disease development. 
- T-bet+ ILC1s are responsive to IL-12 and IL-
15, and can produce IFN-γ contributing to 
disease development. 
(54) 
(55) 
 
(14) 
Type 1 
diabetes 
detrimental 
 
CD4 T 
 
DCs 
- IFN-γ production controlled by T-bet in T 
cells is a contributing factor. 
- T-bet expression in DCs and CD4 T cells is 
required for the initiation and later stage 
pathogenesis, respectively. 
(56) 
 
(57) 
Inflammatory 
arthritis 
detrimental 
 
DCs - T-bet-/- DCs have compromised ability to 
secrete proinflammatory mediators and to 
prime naive T cells. 
(58) 
Asthma beneficial Th2 
 
 
B cells 
- T-bet regulates the Th1/Th2 balance by 
inhibiting Th2 differentiation and IL-4 and IL-
13 production to alleviate asthma. 
- T-bet negatively regulates IgE production. 
(59) 
(60) 
 
(41) 
Allograft 
rejection 
beneficial  Th17 
 
 
Th2, 
Th17 
- T-bet regulates the Th1/Th17 balance by 
inhibiting Th17 differentiation and IL-17 
production to suppress allograft rejection. 
- T-bet-/- RORγt-/- CD4 T cells drive Th2-
mediated allograft rejection. 
(61) 
 
 
(62) 
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1.2 Allo-HSCT, GVHD, and GVL 
            Allo-HSCT, previously known as allogeneic bone marrow transplantation (BMT), is a 
transplant between two genetically non-identical individuals (63), which serves as an important 
therapeutic option to treat various malignant and non-malignant diseases, including, acute and 
chronic leukemias, lymphomas, multiple myelomas, aplastic anemias, solid tumors, and severe 
immunodeficiency disorders (64). There is estimated to be more than 20,000 allo-HSCTs 
performed annually around the world. Some patients present with remission of primary diseases 
after allo-HSCT, however, in many cases patients develop a common secondary complication 
named GVHD, in which transplanted cells injury the host tissues. GVHD accounts for 15–30% 
of deaths following allo-HSCT and is a major cause of morbidity in up to 50% of transplant 
recipients (63). The effectiveness of allo-HSCT for many malignant diseases is due to T-cell 
mediated graft-versus-tumor (GVT) or graft-versus leukemia (GVL) effects. However, allo-
HSCT benefits are frequently offset by the destructive GVHD which is also induced by donor T 
cells (65).  
GVHD has a complex etiology but ultimately is the result of donor T-cells recognizing 
disparate histocompatibility antigens (HA) of the recipient and causing injuries to normal tissues 
(66). Murine models of GVHD are generally grouped into MHC-mismatched, or minor HA-
mismatched situations. GVHD develops in response to a full (class I and II) MHC disparity is 
dependent on CD4 T cells and with additive pathology caused by CD8 T cells. Different from 
CD4-dependent GVHD, CD8-induced GVHD primarily depends on the cytolytic machinery. 
Either CD8 T cells, CD4 T cells, or both, may play a role in minor HA induced GVHD 
depending on the strain combination. A majority of clinical allo-BMT recipients are MHC 
matched but minor HA disparate with the donor, however, there is no one single mouse model to 
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fully represent clinical setting of allo-HSCT (67). There are two forms of clinical GVHD: acute 
GVHD (aGVHD) is characterized by damage to skin, liver, lung, and gastrointestinal tract. 
Patients with aGVHD have increased risk of morbidity and mortality following allo-HSCT. 
Chronic GVHD (cGVHD) has more diverse manifestations and many autoimmune-like 
characteristics. Moderate to severe cGVHD substantially diminishes long-term survival as well 
as quality of life for patients (68). GVHD has been postulated to occur in several stages (66, 69). 
The first stage involves the cytoreductive conditioning and/or immunosuppression, which allows 
for donor cell engraftment. Release of proinflammatory cytokines affects host APCs and helps 
fuel the alloreactive donor T-cell response through alloantigen recognition. This is followed by 
the “induction phase” in which TCR ligation and costimulation combine to achieve full T-cell 
activation and subsequent expansion. As the alloreactive T cells expand, they differentiate into 
different subsets; this is driven by the existence of certain transcriptional factors and cytokines. 
Activated T cells further home to various GVHD target organs, a process controlled by adhesion 
molecules, integrins, and chemokines. The production of chemokines in inflamed and injured 
tissue also results in the recruitment of other cell-types (neutrophils, NK cells, 
monocytes/macrophages) to the GVHD target organs further contributing to tissue injury. The 
“effector phase” is noted for the destruction of host tissue by immune effector molecules (e.g. 
FasL, perforin, granzymes, IFN-γ, and TNF-α) and results in the continued production of 
proinflammatory cytokines that continually fuel the entire GVHD process (Figure. 1.1).  
     The challenge of allo-HSCT for treatment of leukemia and other malignancies of the 
hematopoietic system is the prevention of GVHD without losing the GVL effect. GVL also 
depends on donor T cells that recognize alloantigens and tumor-associated antigens. Various 
strategies have been used in different murine models to successfully separate GVHD from GVL 
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such as: depletion of alloreactive T cells, inhibition of inflammatory cytokines, interfering with 
T-cell cytolytic pathways, co-stimulatory pathways and trafficking, infusing certain subsets of T 
cells, and using immunosuppressive cell populations, including Tregs and NKT cells (70-72). 
Despite its paradigmatic and clinical relevance, the mechanisms involved in the GVL effect are 
still not completely understood and many currently used strategies to prevent GVHD impair T-
cell function with deleterious GVL effects. However, advances are being made gradually by 
documenting the potential of GVHD prevention and even with GVL augmentation, such as the 
strategy of adoptively transfer murine or human Trail+ T cells to induce the fratricide of 
alloactivated donor T cells (73).  
  
 
Figure 1.1 Three phases of GVHD pathophysiology. Acute GVHD has been postulated to occur 
in three sequential phases. (1) The initiation phase starts from conditioning regimen (e.g., 
irradiation) that makes “space” to allow for donor cell engraftment, but also causes host tissue 
damage. Release of proinflammatory cytokines leads to increased expression of MHC and 
adhesion molecules that enhance alloantigen presentation by host APCs to donor CD4 and CD8 
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T cells. (2) The induction phase involves TCR ligation and costimulation to achieve full T-cell 
activation and subsequent proliferation. As the alloreactive T cells expand, they differentiate into 
different subsets. This process is driven by the cytokine milieu through lineage-specific 
transcription factors. Activated T cells release additional inflammatory cytokines, express 
chemokine receptors, and migrate to various GVHD target organs. Chemokine production in 
inflamed tissues recruits other cell types (NK cells, neutrophils, monocytes) to the target organ 
sites, further contributing to GVHD pathology. (3) The effector phase is noted for the destruction 
of host tissue by immune effector molecules, such as perforin, granzymes, IFN-γ, and TNF-α, 
culminating in clinically evident GVHD.  
 
1.3 Helper T-cell differentiation: general pathways and characteristics 
            T-cell activation, proliferation, and differentiation are considered determining factors for 
GVHD development. Naïve CD4+ T cells can commit to particular lineages on the basis of 
different modes of stimulation, antigen concentration, costimulation, and cytokine milieu. It is 
well established that following activation, CD4 T cells will differentiate into either Th1 
(secreting IL-2 and IFN-γ), Th2 (secreting IL-4, IL-5, and IL-13), Th17 (secreting IL-17, IL-21, 
and IL-22), or Tregs (secreting IL-10 and TGF-β) (74). Several newly reported subsets of Th 
cells, such as Th9, Th22, and T follicular helper cells (Tfh), also enriched our understanding 
about T-cell differentiation. (75-77). Acute GVHD has been considered a Th1-type disease based 
on the predominance of cytotoxic T lymphocyte (CTL)-mediated pathology and the increased 
production of Th1-type cytokines, including IFN-γ (78, 79). However, Th17 cells have also been 
implicated in the induction of experimental murine aGVHD (80, 81). In this section, we 
summarize the general paradigms and characteristics among Th cells, including Th1, Th2, Th17, 
and Tregs (Figure1.2).  
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Figure 1.2 Pathways of helper T-cell differentiation: cytokines, transcription factors and 
epigenetic modifications. Upon encountering cognate antigens presented by APCs, naïve CD4 
T cells differentiate into different T helper subsets, including the classic Th1, Th2, Th17, Tregs, 
or more recently defined Th9, Th22, or Tfh effector cells. Cytokines secreted in the 
microenvironment during differentiation play a major role in dictating the phenotype of activated 
CD4 T cells. T-cell lineages are further defined depending on the expression of transcription 
factors, chemokine receptors, and effector cytokines, which are influenced by epigenetic 
modifications. In the standard model, CD4 T cells can differentiate into Th1, Th2, Th17, or Treg 
cells when activated in the presence of IL-12/IFN-γ, IL-4, IL-6/TGFβ, or TGFβ, respectively. T-
bet, GATA3, RORγt, and Foxp3 have been well characterized and considered as the master 
lineage determinants of Th1, Th2, Th17 and Treg cells, accordingly. T-bet leads to gene 
silencing of Th2 and Th17 effector cytokines: IL-4 and IL-17 thus opening chromatin at Th1 
cytokine or chemokine receptor gene loci, such as IFN-γ and CXCR3 activating transcription. 
Likewise, GATA3 causes gene silencing of Th1 and Th17 effector cytokines: IFN-γ and IL-17 
thus activating Th2 effector cytokines IL-4 and IL-13. CD4 T cells may also differentiate into 
Th9, Th22, or Tfh subsets when activated in the presence of IL-4/TGFβ, IL-6/TNF-α, and IL-21, 
respectively. They express lineage specific transcription factors, chemokine receptors, and 
produce effector cytokines. Based on the respective cytokine profiles, responses to chemokines, 
and interactions with other cells; these fully functional Th cells exert specific functions and 
contribute to immune response. Different symbols represent the pathogenicity of different Th 
subsets in GVHD. “+”: pathogenic effect; “-”: protective effect; “?”: non-conclusive effect. 
 
1.3.1 The Th1/Th2 cell paradigm 
            Th1 and Th2 cells have two distinct cytokine secretion patterns that have been defined for  
both murine and human Th cells (82). Mosmann and Coffman initiated Th1/Th2 paradigm in 
1986, when their seminal work was published, which showed that murine CD4+ T-cell clones 
could be characterized not only on the basis of their antigen specificity but also by their 
functional skill sets, defined initially by differential cytokine secretion profiles (83). This 
paradigm was further strengthened by equivalent findings from other groups, proving Th1 cells 
distinctively produce IFN-γ, lymphotoxin, IL-2 and TNF-α. In contrast, Th2 cells produce their 
signature cytokines: IL-4, IL-5, and IL-13. However, Th2 cells do produce lower levels of TNF-
α, GM-CSF, and IL-2 than Th1 cells (84, 85). Beyond the studies on lineage-specific cytokines, 
critically important work from the groups of Zheng and Flavell (86) and Szabo et al. (1) further 
identified lineage-specific transcription factors for Th1 and Th2 cells in mice. T-bet (Tbx21) was 
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found to be the critical transcription factor for the generation of Th1 cells, whereas GATA3 
served that role for Th2 cells. Evidence provided by different studies strongly suggests that the 
cytokines play a major role in inducing the transcription factors that determine T-cell 
differentiation (18, 87). Th1 cells are triggered by IL-12 and IFN-γ, and Th2 cells are triggered 
by IL-4. With growing experience it has become clear that for Th1 and Th2 cells specialization 
in patterns of cytokine production, transcription factors and other phenotypic characteristics do 
occur in mice and in humans. The Th1/Th2 paradigm has been accepted for more than 20 years 
(85). The differential development of these subsets allows for protective immunity against 
specific pathogens. Th1 cells are important in mediating cellular immune responses and play a 
critical role in the clearance of intracellular pathogens, whereas Th2 cells are mainly involved in 
humoral immunity such as allergic immune responses and anti-parasitic immunity (88). 
 
1.3.2 Differentiation and characteristics of Th17 cells 
            Th17 cells are highly proinflammatory cells that are part of the adaptive immune 
response mounted against extracellular pathogens and also have been implicated in the induction 
of several autoimmune diseases in mice (89). In the past nine years, an accumulation of 
information on this popular T-cell subset (Th17) has been witnessed in both humans and mice: 
The cytokines for its differentiation and expansion have been identified and the key transcription 
factors that are involved in its generation have been elucidated (90). Murine IL-23 has long been 
recognized to be an inducer of IL-17 (91). However, naïve murine T cells do not express the IL-
23R and do not differentiate into Th17 cells in the presence of IL-23 in vitro (92). Therefore, IL-
23 cannot be the sole inducer of Th17 differentiation although it appears to have a role in the 
maintenance of effector function once these cells are induced (93). Other cytokines such as IL-6 
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and IL-21 are implicated in the regulation and induction of IL-17 production by using gene 
deficient mice (94, 95). In vitro, IL-6 is a potent inducer of Th17 cells but only when combined 
with other cytokines including TGF-β (96). Thus, it appears the conjunction of TGF-β with IL-6 
is the initial drivers of Th17 specification, and they can also activate the transcription factor 
STAT-3, which is required for murine Th17 differentiation (97). However, full expression of the 
Th17 phenotype depends on RORγt, which induces the expression of IL-17 and IL-17F, 
contributes to the generation of IL-23R, and mediates IL-22 production in mice (98). In the 
absence of IL-6, IL-21 in combination with TGF-β can function as an alternative signal for the 
induction of Th17 cells (95). In disease models such as EAE that depend on Th17 induction, IL-6 
seems to be more relevant than IL-21 (99). Other proinflammatory cytokines such as TNF-α and 
IL-1β have also been shown to facilitate Th17 differentiation (100, 101). 
Th17 cells are characterized by the production of several distinct cytokines that are not 
typically secreted by Th1 and Th2 cells. In addition to the signature cytokine IL-17, Th17 cells 
also preferentially secrete IL-17F, IL-21, IL-22, and, in humans, IL-26 (102). These cytokines 
play important and non-redundant roles in enhancing the host defense against extracellular 
pathogens. The receptors for IL-17 and IL-22 are broadly expressed on various epithelial tissues. 
Thus, Th17 cells play critical roles in tissue immunity by mediating the crosstalk between 
immune system and parenchymal tissues. 
 
1.3.3 Interaction of Th17 cells with Th1, Th2, and Tregs 
A balanced interaction among various T-cell subsets is very important in maintaining 
immune homeostasis. Th1 and Th17 cells have a proinflammatory role and have been implicated 
in many inflammatory conditions in humans and mice (103), while an anti-inflammatory role is 
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attributed to Th2 and Treg cells. Th1 and Th2 cells inhibit the development of each other through 
the actions of their lineage-specific cytokines IFN-γ and IL-4, respectively (104, 105). This 
principle fits for Th17 cells as well, since the differentiation of Th17 cells can be inhibited by 
IFN-γ or IL-4. However, once fully differentiated, Th17 cells are resistant to the suppressive 
effects of IFN-γ and IL-4 in vitro (106, 107). Coexistence of Th17 and Th1 cells in inflammatory 
lesions suggest their possible redundant function in pathology of murine experimental 
autoimmune uveitis (108). 
Another important aspect of Th17 cell differentiation is their relationship with Tregs. 
Tregs can follow a developmental path similar to other T cells and emerge from the thymus 
(referred tTreg or frequently as nTreg, for natural) or differentiate extrathymically from naïve 
CD4+ T cells; Tregs in the latter subset are known as peripherally induced Treg cells (referred 
pTreg, or frequently as iTreg, for induced) (109, 110). Tregs are critical for the maintenance of 
immunological homeostasis and self-tolerance in humans and mice (111). These cells have been 
classically defined as being CD4+ CD25+ and expressing the transcription factor Foxp3 (112). 
Development of Th17 or Treg cells from induced murine naïve T cells has been suggested under 
a mutually exclusive manner (113). IL-6 plays an important role in regulating the balance 
between Th17 cells and Tregs in humans and mice. IL-6 induces the development of Th17 cells 
from naïve T cells together with TGF-β; in contrast, IL-6 inhibits TGF-β-induced Treg 
differentiation (114). Thus, IL-6 acts as a potent proinflammatory cytokine through promotion of 
Th17 differentiation and inhibition of Treg differentiation indicating that this cytokine alters the 
balance between effector and regulatory T cells. Moreover, Foxp3 itself is able to associate with 
ROR-γt and inhibit ROR-γt transcriptional activation in mice (115).  
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1.4 Helper T-cell subsets in GVHD: experimental and translational evaluations 
GVHD is a major complication of allo-HSCT. Most of the knowledge about the 
pathophysiology of GVHD has been derived from studies in mouse models. The differentiation 
of Th cells requires coordinated cytokine signaling that induces the activation of specific 
transcription factors and the production of linage specific cytokines to promote lineage-specific 
CD4+ T-cell differentiation. Here we summarize the experimental and translational evaluations 
of Th-cell subsets in GVHD, including the roles of important transcription factors and effector 
cytokines, and their reciprocal differentiation features. 
 
1.4.1 Transcription factors involved in T-cell differentiation in GVHD 
The molecular mechanism by which a Th precursor adopts a Th1, Th2, Th17, or Treg 
phenotype involves a complex interplay between the induction of lineage specific transcription 
factors, such as T-bet, GATA3, RoRγt, and Foxp3, and the stimulatory effects of the cytokine 
milieu which are largely provided by host APCs (116).   
1.4.1.1 Th1: T-bet, STAT1, STAT4, c-Rel.  Several transcription factors in coordination 
induce full Th1 differentiation, including T-bet, STAT1, STAT4, and c-Rel. As one of the master 
regulators that shape immune responses, T-bet has a unique role in the differentiation of all three 
subsets (Th1, Th2, Th17) of CD4+ Th cells by promoting the Th1 differentiation, while 
simultaneously inhibiting the opposing Th2 and Th17 lineage commitment (24). T-bet also 
controls the expression of a subset of genes encoding molecules that influence the migration and 
homeostasis of Tregs during Th1 cell-mediated immune responses (24). T-bet is a transcriptional 
activator of IFN-γ (1), and the key regulator for the Th1 differentiation program. T-bet 
orchestrates Th1 migration by directly controlling expression of chemokine receptor CXCR3 and 
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chemokines CCL3 and CCL4 (117, 118). T-bet can also function as a repressor of certain genes 
such as Socs1, Socs3, and Tcf7, that promotes the development of Th1 fate. T-bet physically 
associates and functionally recruits the transcriptional repressor Bcl-6, to the Socs1, Socs3, and 
Tcf7 promoter regions and represses their transcription (119). The repression of Socs family 
members Socs1 and Socs3 is necessary to create functional Th1 cells. The repression of Tcf7 will 
inhibit Th2 fate by sequestering the Th2-specific transcription factor GATA3 away from the Il5 
and Il13 promoters. Runt-related transcription factors also participate in the differentiation 
process. Runx1 and Runx3 were found to promote Th1 cell differentiation in coordination with 
T-bet (29, 120). T-bet and Runx3 bind to Il4 silencer and prevent Il4 expression (24). In Th17 
cells, T-bet interacts with Runx1 and blocks Runx1-mediated transactivation of Rorc, then 
suppresses the Th17 lineage development (24). Our group previously showed targeting T-bet and 
RORγt can prevent GVHD without offsetting GVL activity in allo-BMT murine models (47). 
Our recent study also found that T-bet is critical for CD4 T-cell-mediated GVHD by controlling 
T-cell differentiation and function, also the involvement of T-bet-dependent but IFN-γ-
independent molecules can partially explain the compromised ability of T-bet deficient but IFN-γ 
sufficient CD4 T cells in murine GVHD induction (46). 
STAT1 is another main signal transducer for IFN-γ (121). In response to IFN-γ 
stimulation, STAT1 is activated and then initiates Th1 development. T-bet is induced by IFN-γ 
and STAT1 signal pathway upon T-cell activation. Once triggered, T-bet in turn activates IFN-γ 
expression, leading to autocrine and paracrine positive feedback effects on IFN-γ/STAT1 
signaling and further controls Th1 differentiation (17). STAT1 activation in GVHD target tissue 
and secondary lymphoid organs is one of the earliest events in GVHD induction (122). Ma et al. 
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(123) showed that absence of STAT1 in donor CD4+ T cells promotes the expansion of Tregs 
and reduces GVHD in mice.  
STAT4 is another important transcription factor involved in the Th1 cell differentiation 
(124). By inducing IFN-γ production, STAT4 creates a positive feedback loop for further T-bet 
and IL-12Rβ2 expression. At later stages of differentiation, IL-12/STAT4 pathway upregulates 
expression of IL-18Rα. IL-12 along with IL-18 induces IFN-γ production, independent of TCR 
activation, thus creating a pathway for enhancing Th1 response (125). Nikolic et al. (126) 
evaluated the role of STAT4 or STAT6 in the induction of aGVHD using gene deficient mice as 
donors, and found that STAT4–/– donor T cells mediated aGVHD with delayed kinetics 
compared with wild-type (WT) or STAT6–/– T cells. On the other hand, STAT6 was 
indispensable for liver and skin GHVD. 
c-Rel controls CD4 T-cell differentiation during diverse immune responses by using both 
T-cell autonomous and nonautonomous mechanisms (127). Hlx, another transcription factor and 
Th1 cell-specific homeobox protein, has been shown to synergize with T-bet in promoting the 
transcription of IFN-γ (128). One explanation is that c-Rel might indirectly regulate the 
expression of IFN-γ by controlling the levels of Hlx. The defect in IFN-γ production by c-Rel-
deficient Th1 cells could also be due to a remodeling failure at IFN-γ locus (129). Alternatively, 
c-Rel could be involved in a pathway parallel to T-bet or serve as a common effector molecule 
downstream of T-bet and STAT4 pathways. Thus, the precise position of c-Rel in the hierarchy 
of the Th1 transcriptional cascade leading to the production of IFN-γ has not been defined yet. 
Our group recently found that (130) T cells deficient for c-Rel have a dramatically reduced 
ability to cause aGVHD after allo-BMT by using major and minor histocompatibility 
mismatched murine models. Our data showed that c-Rel–/– T cells had a reduced ability to 
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expand in lymphoid organs and to infiltrate in GVHD target organs in allogeneic recipients. c-
Rel–/– T cells were defective in the differentiation into Th1 cells after encountering alloantigens, 
but were enhanced in the differentiation toward Foxp3+ Treg cells. Furthermore, c-Rel–/– T cells 
had largely preserved activity to mediate GVL response. Thus, c-Rel plays an essential role in T 
cells in the induction of aGVHD. 
1.4.1.2 Th17: RORγt, STAT3, AhR, and IRF4. The development of Th17 cells is 
mainly dependent on the transcription factors RORγt, STAT3, AhR, and IRF4 (98, 131). RORγt 
together with RORα synergistically directs the differentiation program of Th17 lineage and their 
absence completely aborted Th17 development (131). Fulton and colleges (132) have evaluated 
the role of Th17 cells in murine aGVHD by infusing donor T cells lacking Rorc. Their data 
suggests that Rorc deficient T cells have reduced ability to induce aGVHD. However, our study 
demonstrated that (47) RORγt alone plays little role on donor T cells in the induction of aGVHD, 
but RORγt significantly control the T-cell pathogenesis in aGVHD in the absence of T-bet. Thus, 
targeting both T-bet and RORγt can effectively prevent GVHD without offsetting GVL activity 
in murine models of allo-BMT (47).   
As one of GVHD-specific signaling pathways, STAT3 plays an important role in the 
differentiation process by activating downstream IL-6, IL-21, and IL-23 signaling. It can also 
induce RORγt expression by binding to IL-17A and IL-17F promoters (133). Deficiency of 
STAT3 causes enhanced expression of T-bet and Foxp3, which are involved in the development 
of opposing Th1 and Treg lineages, respectively (134). Ma et al. (135) reported that, STAT3 
activation in the spleen correlated with high levels of IL-6 and IL-10. The marked change in IL-
6/IL-10 ratio during the development of GVHD could suggest that STAT3 may act as a promoter 
of inflammation during the early priming and induction phase of GVHD (high IL-6/IL-10 ratio) 
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and may mediate anti-inflammatory signals at later time points (low IL-6/IL-10 ratio). A study 
from Lu et al. (136) also provides evidence that STAT3 and ERK1/2 phosphorylations are 
critical for T-cell alloactivation and GVHD. Furthermore, by using conditional STAT3 knockout 
mice as donors, Radojcic et al. (137) demonstrated that STAT3 is critical for CD4-driven 
cGVHD.  
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor with important 
physiological roles in biological responses, such as controlling cell proliferation and 
inflammation. Studies suggest that AhR promotes Th17 differentiation through the inhibition of 
STAT1 and STAT5. However, absence of AhR did not completely abort Th17 differentiation, 
but was associated with inability to produce IL-22 (138, 139). Activation of AhR by its 
prototypic ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), induces potent suppression of 
aGVHD in mice. Suppression is associated with development of a regulatory population of donor 
CD4+ CD25+ T cells, but is independent of CTLA4-IFN-γ-IDO pathway (140). 
BATF/IRF4 complexes are also involved in the transcriptional network to control Th17 
differentiation. Cooperatively bound BATF and IRF4 contribute to the initial chromatin 
accessibility and play a central role in RORγt-mediated activation of Th17 molecular signatures 
(141). IRF4–/– mice failed to enhance expression of RORγt and subsequently did not develop 
EAE as a result of impaired Th17 response (142). However, the role of IRF4 in the pathogenesis 
of GVHD needs to be further investigated. 
1.4.1.3 Tregs: Foxp3. As an important subset of Th cells, roles of Tregs in GVHD have 
been widely investigated by us and others (143-146). Accumulating studies clearly indicate that 
regulatory CD4+ T cells play a vital role in attenuating GVHD and are critically important for the 
maintenance of tolerance (147-149). Tregs appear to uniquely express the Foxp3 transcriptional 
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repressor. Foxp3 expression negatively correlated with the severity of GVHD in patients (150). 
Clinical studies on recipients receiving BMT suggest that antigen-specific CD4+CD25+Foxp3+ T 
cells play a critical role in the regulatory control of GVH reactions mediated by both alloreactive 
and autoreactive lymphocytes (151).  
 
1.4.2 Effector cytokines of distinct T-cell subsets: contribution to GVHD 
1.4.2.1 Th1: IFN-γ, TNF-α, and IL-2. Acute GVHD has been proposed to be induced 
by Th1 cells based on the predominant increased production of Th1-type cytokines, including 
IFN-γ, TNF-α, and IL-2, which are detected in serum or donor T cells during aGVHD in both 
humans and mice (152, 153). Paradoxically, the principal Th1 cytokine IFN-γ appears to be 
unnecessary for GVHD induction and it can even inhibit the development of GVHD in lethally 
irradiated allo-HSCT recipients (154-157). One study (155) showed that CD4+ T cells from IFN-
γ–/– mice resulted in accelerated GVHD after lethal total body irradiation (TBI) using a single 
MHC- II mismatch model. In sharp contrast, the use of these same IFN-γ–/– CD4+ donor cells in 
combination with sublethal TBI significantly ameliorated GVHD-associated mortality. 
Administration of anti-IFN-γ antibodies to sublethally irradiated recipients of WT donor cells 
confirmed the role of IFN-γ neutralization in CD4+ T-cell-mediated GVHD. Thus, opposite roles 
of IFN-γ on CD4-mediated GVHD were shown to depend on different irradiation conditions. 
The absence of IFN-γ is protective against GVHD in models using sublethal TBI, whereas 
deleterious GVHD occurs in lethal TBI conditioning. Further studies indicate that IFN-γ plays a 
protective role in lung, but a detrimental role for gut tissues (158, 159). IFN-γ specifically 
suppresses lung GVHD through IFN-γR signaling in lung parenchymal cells (160, 161).  
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TNF-α has been implicated to be involved in the pathophysiology of GVHD at several 
steps. It participates in the initiating stage and amplifies the disease progression once established. 
A series of clinical experiments demonstrated the strong correlation between TNFR1 levels and 
GVHD supporting the importance of TNF-α in this process (162). Cooke et al. (163) found that 
donor resistance to lipopolysaccharide significantly reduces the severity of aGVHD after 
allogeneic BMT and that attenuation of early intestinal toxicity mediated by TNF-α is 
responsible for this effect. TNF-α has both direct and indirect effect on GVHD: TNF directly 
induce apoptosis on target tissues, and TNF indirectly activates T-cell proliferation pathways. 
TNF-α has been used as a therapeutic target in preclinical GVHD models with promising results. 
Soluble TNF receptors or monoclonal antibodies can be used to inhibit TNF-α 
pharmacologically. Korngold et al. (164) have found that a chimeric rat/mouse anti-TNF-α mAb 
could reduce the development of GVHD but preserve the GVL responses in murine models, with 
a more significant effect in CD4- rather than CD8-mediated disease. Inﬂiximab is a genetically 
constructed IgG1 murine-human chimeric monoclonal antibody against TNF-α. Binding of 
infliximab to the soluble subunit of TNF-α blocks the interaction of TNF-α with its receptors and 
causes cell lysis. Inﬂiximab was proven to be well tolerated and active for the treatment of 
steroid-resistant aGVHD in patients (165). Further investigations are ongoing to define the 
optimal dose and duration of TNF-α inhibition for GVHD prevention and treatment. 
IL-2 was initially described as a T-cell growth factor. Given this knowledge, IL-2 
treatment was initially used as a strategy to augment immune responses in cancer. Despite high 
doses of IL-2 this treatment only induced modest antitumor responses; it also caused substantial 
toxicities in patients with metastatic melanoma (166). Because IL-2 is a stimulant in the immune 
environment, it initially has been expected to exacerbate GVHD rather than relieve it. But earlier 
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studies found that IL-2 inhibits GVHD-promoting activity of CD4+ cells while preserving CD4- 
and CD8-mediated GVL effects in mice (167). Two recent clinical studies (168, 169) using much 
lower doses of IL-2 in different immune-mediated diseases suggesting that IL-2 may have a 
dominant role in immunosuppression rather than in immune stimulation. It may also explain the 
equivocal effects of IL-2 treatment seen in earlier clinical trials. Low dose of IL-2 administration 
in patients after allo-HSCT suppressed the occurrence of cGVHD (168) and improved vasculitis 
arising from chronic HCV infection (169). Increased numbers of Tregs were observed after IL-2 
treatment in both studies. Given that Tregs have a high affinity for IL-2, meaning they bind 
especially well to IL-2 at low concentrations, researchers theorized that low doses of IL-2 could 
activate Tregs to a far greater extent than conventional effector T cells, thereby reducing the 
immune response causing cGVHD (168). Another preclinical study showed the synergistic 
effects of rapamycin and IL-2, displayed by increased expansion of donor-derived Tregs and 
reduced lethal aGVHD in mice (170). IL-2 sets an example to represent the complex dynamic 
state of the immune system involving both suppression and activation.  
1.4.2.2 Th17: IL-17, TGF-β, IL-21, IL-23, and IL-6. Among investigators, a conclusive 
role of IL-17 in GVHD development has not yet reached a consensus. Adoptive transfer of 
highly purified ex vivo polarized murine Th17 cells results in a more aggressive disease that is 
dependent on IL-17 (80, 81). However, IL-17−/− donor CD4+ T cells could attenuate, exacerbate, 
or had no effect on GVHD depending on the model and knockout mouse strains used (159, 171, 
172). Kappel et al. (171) found that IL-17−/− total T cells induced similar GVHD responses as 
WT cells, although, when purified CD4+ IL-17−/− T cells were given, there was improved 
outcomes regarding the prolonged median survival. They conclude that IL-17 contributes to the 
early development of CD4+ T-cell-mediated GVHD by promoting production of 
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proinflammatory cytokines; however, it is dispensable for GVHD and GVT activity by 
unfractionated T cells. Yi et al. (172) obtained substantially different results using a similar 
murine BMT model. IL-17−/− T cells were found to exacerbate GVHD and to accelerate recipient 
mortality compared with WT T cells. Administration of exogenous IL-17 or neutralizing IFN-γ 
could prevent the deleterious outcomes seen with IL-17−/− cells. This leads the investigators to 
conclude that GVHD is exacerbated due to the augmentation of Th1 differentiation.  
TGF-β plays critical roles in two antagonistically related Th cell subsets, Th17 and iTreg 
cells. The conjunction of TGF-β with IL-6 is the initial driver of Th17 specification. Hill’s group 
demonstrated that (173) neutralization of TGF-β after allo-BMT significantly increased aGVHD 
severity in mice and the concurrent prevention of IL-10 production further exaggerated this 
effect. Early after allo-BMT, donor T cells were the predominant source of TGF-β and were able 
to alleviate aGVHD in a TGF-β-dependent manner. Although the neutralization of TGF-β 
augmented the proliferation and expansion of donor T cells after allo-BMT, it paradoxically 
impaired cellular cytotoxicity to host antigens and associated GVL effects. Different from the 
protective effects in aGVHD, TGF-β contributed to the severity of cGVHD after allo-BMT. 
IL-21 is produced by CD4+ T cells, especially Th17 cells (174) and NKT cells (175) 
which signals through the IL-2Rγc and IL-21R complex. Recent reports show that inhibiting IL-
21 decreases disease severity in murine models of GVHD (176, 177). Genetically disrupting IL-
21 signaling or by using neutralizing mAbs could reduce transplant-related weight loss, tissue 
pathology, and mortality. Disease amelioration correlated with decreased numbers of CD4+ T 
cells secreting IFN-γ and a concomitant increase in the proportion of CD4+ T cells expressing 
Foxp3, which is due to the conversion of CD4+ CD25− T cells into iTregs rather than preferential 
expansion of nTregs themselves (176). Critical differences exist in how IL-21 functions in mouse 
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and humans. IL-21 can act as the second signal required for Th17 polarization in humans (178), 
whereas only IL-6 but not IL-21, has this function in mice (113). Blazar’s group established a 
human xenogeneic GVHD model (179), and found that treatment of neutralizing mAb of human 
IL-21 lead to significantly reduced GVHD-associated weight loss, mortality, increased Tregs, 
and a decrease in T cells secreting IFN-γ or granzyme B in recipient mice. Based on these 
findings, anti-IL-21 mAb could be considered for GVHD prevention in clinic. 
By using genetic and antibody-based strategies, Das et al. (180) examined the effect of 
blocking of IL-23 signaling on GVH and GVL activity after allo-BMT in mice. They 
demonstrated that IL-23 blockade selectively protects the colon, specifically by attenuating gut 
injury while still preserving the GVL effect. Interestingly, the colon did not serve as a sanctuary 
site for subsequent systemic relapse in GVHD-protected mice since a potent GVL response 
could be mounted in this organ under conditions where tumor cells migrated to this site. Thus, 
blockade of IL-23 signaling is an effective strategy for separating GVH and GVL responses. IL-
23 could be a potential therapeutic target for the regulation of alloresponses in humans. 
As a pivotal inflammatory cytokine in immune system, IL-6 plays important roles in 
altering the balance between the effector and regulatory arms. It also drives a proinflammatory 
phenotype that defines GVHD characteristics. Studies show that inhibition of the IL-6 signaling 
pathway, by antibody-mediated blockade of the IL-6 receptor (IL-6R), markedly reduces 
GVHD-caused pathologic damage in mice (181). This is accompanied by a significant increase 
in the absolute number of Tregs and a significant reduction of Th1 and Th17 cells in GVHD 
target organs. This demonstrates that blockade of IL-6 signaling decreases the ratio of 
proinflammatory T cells to Tregs. However, another group (182) showed that a brief duration of 
IL-6 inhibition in recipient mice did not increase the absolute numbers of mature donor Tregs. 
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This could be a consequence of the several key differences between the models, including the 
dose of radiation, the infusion of unsorted splenocytes, and the duration of IL-6 blockade. Thus, 
blockade of IL-6 with anti–IL-6R mAb therapy may be testable in clinical trials to prevent 
GVHD in allo-BMT. 
 
1.4.3 Reciprocal differentiation of Th1, Th2, and Th17 cells in GVHD 
In addition to the well-established balance between regulatory and effector T cells, the 
balance among Th1, Th2, and Th17 effector subsets also plays an important role in regulating T-
cell immune response. In aGVHD, naïve donor CD4+ T cells recognize alloantigens on host 
APCs and differentiate into Th subsets, but the role of Th subsets in GVHD pathogenesis was 
incompletely characterized until six years ago when Yi et al. (159) published their study in which 
they discussed the reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and 
Th17 cells in GVHD. They found that in an MHC-mismatched murine model (C57BL/6 → 
BALB/c), donor CD4+ WT T cells predominantly differentiated into Th1 cells and preferentially 
mediated tissue damage in the gut and liver. However, deficiency of IFN-γ in CD4+ T cells 
enhanced Th2 and Th17 differentiation and exacerbated tissue damage in the lung and skin. 
Absence of both IL-4 and IFN-γ augmented Th17 differentiation and caused preferential skin 
damage. Deficiency of both IFN-γ and IL-17 led to further augmentation of Th2 differentiation 
and idiopathic pneumonia. The tissue specific GVHD pathology elicited by Th1, Th2, and Th17 
cells was partially associated with their tissue-specific migration, which is dependent upon 
differential expression of chemokine receptors. Several studies have described the increased 
expression of chemokines and chemokine receptors in GVHD (183, 184). The profile of 
chemokine and chemokine receptor expression is diverse in different target organs of GVHD. 
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The results obtained by Yi et al. (47) indicate that donor CD4+ T cells can reciprocally 
differentiate into Th1, Th2, and Th17 cells, and each Th subset contributes to specific GVHD 
target organ tissue damage. This study further enriches the content of the standard model for Th 
differentiation, especially in aGVHD settings. Although Th2 cells may still be pathogenic to 
certain tissues (e.g. lung), our recent work demonstrated that Th1 and Th17 subsets are the 
primary driving force to induce aGVHD in mice, thus targeting these two subsets while 
preserving or promoting Tregs may represent an effective strategy to control aGVHD (47). 
 
1.5 Helper T-cell subsets in GVHD: clinical strategies 
 
1.5.1 Current findings of the role of T-cell subsets in clinical GVHD 
The pathogenesis of GVHD involves various Th-cell subsets. Each individual disease 
manifestation appears to have a distinct T-cell milieu, which is determined by target structure 
and inflammatory environment. Several aspects contribute to the understanding of T-cell subset 
function in humans including cytokine quantifications in peripheral blood, lesion tissue biopsies, 
or from single nucleotide polymorphisms (SNPs) of cytokine genes and their association with 
GVHD (185-187). Much of the information about the role of T-cell subsets in clinical GVHD is 
confusing and contradictory, which indicates that, the picture of GVHD etiology is likely more 
complex in humans.  
Despite the perceived skewing of GVHD toward a Th1 process, no study has found 
increased serum levels of IL-12 in the patients after allo-HSCT compared with healthy donors 
(188). Consistently, investigators have found increased expression for IL-6, TNF-α, and IL-1β, 
which correlated with either disease severity (189, 190) or disease onset (186). Zhao et al. (191) 
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found that, donor-derived Th17 cells in the allografts emerged as the independent risk factor 
during the course of aGVHD in human, which suggests that IL-17-producing cells might be a 
type of initiating cell in aGVHD. Recently, The Japan Donor Marrow Program analyzed 
rs2275913, a SNP within the promoter region of the IL-17 gene and found that patients with this 
SNP had increased IL-17 secretion increasing their risk of aGVHD (192). G-CSF treatment in 
vivo reduced the occurrence of aGVHD through decreasing IL-17 production by T cells. In 
accordance with the study reported by Zhao et al. (191), Dander et al. (193) found that the 
peripheral blood of patients with ongoing GVHD showed an increased number of IL-17-
secreating T cells after transplantation, not surprisingly this increase was associated with the 
clinical course of aGVHD. In contrast, Ratajczak et al. (194) demonstrated that Th17 cells in 
human GVHD was not associated with any evidence of severe tissue damage at the onset of 
disease, but the Th17/Treg ratio detected in lesion biopsies from gastrointestinal tract and skin is 
positively correlated with the severity of aGVHD and serves as a sensitive and specific marker of 
human GVHD. In addition, they detected significantly more IFN-γ producing T cells in biopsies 
from affected areas. This data suggests that detection of individual T-cell subsets might not be 
sufficient to reflect the complicated immune processes in human GVHD. 
 
1.5.2 New approaches to target T-Cell differentiation for controlling GVHD in clinic  
Tocilizumab, a humanized anti-IL-6R mAb, has been approved in several countries for 
the treatment of rheumatoid arthritis and other inflammatory diseases. Administration of 
tocilizumab has been reported to effectively reduce GVHD severity in the gastrointestinal tract 
as determined by a marked reduction in the volume of diarrhea (195). A small-scale clinical 
study in GVHD patients indicates that tocilizumab has activity in the treatment of steroid 
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refractory GVHD (196). Tocilizumab is currently under phase I clinical trial and the expected 
effects are to decrease Th17 differentiation while increasing Treg induction in GVHD patients 
(149). However, Betts et al. (197) did not observe an effect of tocilizumab on human monocyte-
derived dendritic cells maturation and activation, alloreactive T-cell proliferation, Treg 
expansion, or allogeneic Th1/Th17 responses in vitro, despite its on-target suppression of IL-6R 
signaling (Figure 1.3). Therefore, the efficacy of tocilizumab on GVHD regulation warrants 
further evaluation in clinic.  
 
 
Figure 1.3 Therapeutic strategies to control GVHD by targeting of T-cell differentiation. (1) 
Ustekinumab, anti-p40 mAb, binds to p40 subunit of IL-12 and IL-23 preventing their 
interaction with IL-12Rβ1 on the T cell surface, thus, inhibiting IL-12 and IL-23 signaling.  As 
the consequence, Ustekinumab is expected to reduce the differentiation to Th1 and Th17 while 
promoting the differentiation towards Th2 and Tregs. (2) Tocilizumab, anti-IL-6R mAb, 
interferes IL-6 binding to IL-6R either membrane bound or soluble form, thus preventing the 
dimerization of signal transducer gp130 and its interaction with IL-6/IL-6R complex. Treatment 
 30 
 
is expected to result in blocking Th17 differentiation and enhancing Treg generation. (3) 
Rapamycin inhibits mTOR activation. In conventional T cells, diverse signals determine mTOR 
activity, including ligated costimulatory molecule CD28, TCR, the cytokine IL-2, and its 
receptor. Among the complex networks, signals are transduced through PI3K–AKT-mediated 
pathway to activate mTOR. Upon activation, mTOR promotes Th1, Th2, and Th17 
differentiation but reduces Treg differentiation by regulating their lineage specific transcription 
factors. mTOR functions as part of the complexes mTORC1 and mTORC2. Rapamycin in 
complex with the immunophilin FK506-binding protein 1A, 12 kDa (FKBP12) inhibits 
mTORC1 and decreases the T-cell differentiation towards Th1, Th2, and Th17 while enhancing 
Tregs. (4) Statins, HMG-CoA reductase inhibitor, blocks the conversion of HMG-CoA to 
mevalonate and thereby prevents the formation of cholesterol and isoprenoids, which leads to the 
inhibition of isoprenylation of small GTPases such as Ras, Rho, and Rac. This influences 
multiple intracellular signaling pathways and cellular functions including proliferation and 
differentiation. Statins causes preferential development of Th2 cells, as well as Tregs, and 
inhibition of Th1-driven responses. 
 
Ustekunimab (Stelara) is a humanized monoclonal antibody that directly binds to p40, a 
subunit shared by IL-12 and IL-23. As a treatment utilized to regulate the immune-mediated 
inflammatory disorders such as psoriasis, ustekunimab had not been previously used for GVHD 
until Pidala et al. (198) observed its activity in a patient with advanced refractory aGVHD. 
Ustekinumab was successful in inducing clinical remission of aGVHD in that patient and the 
correlative data on peripheral blood serum cytokine production indicated the skewing of CD4+ 
T-cell repertoire from Th1 to Th2 and Tregs. Given that IL-12 and IL-23 are key drivers of the 
differentiation of Th1 and Th17 cells responsible for GVHD (199, 200), use of ustekunimab to 
target against both Th1 and Th17 may provide a powerful novel approach for GVHD prevention 
(Figure 1.3). A comparative trial, lead by Dr. Pidala, is currently ongoing to assess the biologic 
and clinical activity of ustekinumab in GVHD patients when given in concert with the 
established regimen of sirolimus/tacrolimus. 
Rapamycin (Sirolimus), a macrolide antibiotic produced by Streptomyces hygroscopicus, 
is the prototypical inhibitor of the molecular target of rapamycin (mTOR). It has been used as a 
prophylaxis and treatment in a number of immune disorders including GVHD (201, 202). Pidala 
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et al. (203) provided preliminary evidence for the efficacy of sirolimus as a sole primary therapy 
in the treatment of aGVHD. In a series of ten patients at high risk for corticosteroid toxicity or 
leukemia relapse who developed grade II–III aGVHD after allo-HSCT, it was reported that 
primary therapy with sirolimus resulted in durable complete remission of aGVHD in 5 (50%) 
without requirement for glucocorticoids. Projected overall survival at 18 months is 79% and 
projected relapse-free survival at 15 months is 70%. Several studies recently have reported the 
use of gene targeting to disrupt mTOR function in lymphocytes conﬁrming an essential role for 
mTOR signaling in T-cell differentiation (204). Complete deficiency of mTOR signaling (both 
mTORC1 and mTORC2) abrogated the differentiation of Th1, Th2, and Th17 lineages, and 
instead T cells were diverted into a Foxp3+ regulatory phenotype. This was associated with 
reduced levels of activation of STAT transcription factors and subsequent failure to induce 
expression of the Th1, Th2, and Th17 master regulators T-bet, GATA3, and RORγt (205). 
Different groups report distinct roles for mTORC1 and mTORC2 in T cells although with 
discrepancies (205, 206). Rapamycin induces in vitro expansion of nTreg (207), which has also 
been used recently to establish good manufacturing practice for expansion protocols for human 
CD4+CD25+ T cells (208). Rapamycin and IL-2 enable the expansion of donor-derived nTreg 
and conversion of CD25– T cells to iTreg, which potently inhibits GVHD development in vivo 
(170). Thus, the application of rapamycin in combination with IL-2 to get higher yields of nTreg 
and iTreg represents a promising strategy of pharmacologic Treg modification to treat or prevent 
GVHD (Figure 1.3). The main oral alternative to sirolimus is everolimus with slightly improved 
bioavailability and the use of everolimus in refractory cGVHD has been reported by Lutz et al. 
during the 38th Annual Meeting of the European Group for Blood and Marrow Transplantation in 
Switzerland (209). Sirolimus and everolimus are currently under phase II/III or phase I clinical 
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trials, respectively, and the expected effects are to decrease Th1 cell differentiation and retain or 
increase Treg cells in GVHD patients (149).  
HMG-CoA reductase inhibitors (statins) are prescribed worldwide for the prevention and 
treatment of dyslipidemia and atherosclerosis (210). Statins can bind to HMG-CoA reductase 
and displace its natural substrate HMG-CoA, leading to inhibition of mevalonate and cholesterol 
biosynthesis. Cholesterol metabolism has been indicated to play an important role in modulating 
T-cell proliferation and differentiation through liver X receptor signaling (211, 212). Stains can 
also indirectly inhibit several posttranslational modification proteins such as Ras, Rho, and Rac, 
through reduced mevalonate production (210). Thus, statins can further effect multiple 
intracellular signaling pathways and cellular functions including differentiation, motility, 
secretion, and proliferation (213). Atorvastatin is the prototypic statin drug that has a proven 
safety track record (214). Inhibiting Ras leads to preferential development of Th2 cells and 
inhibition of proinflammatory Th1-driven responses (213). This change in intracellular signaling 
may also effect the development of Treg cells, as exposure of human CD4+ T cells to 
Atorvastatin in vitro increased expression of Foxp3. Furthermore, patients with hyperlipidemic 
who took statins up to eight weeks had more circulating Foxp3+ Treg cells (215). In addition to 
direct effects on T cells, statins inhibit IFN-γ-induced expression of MHC-II and block 
upregulation of a variety of costimulatory molecules and cytokines in APCs (213). Hamadani et 
al. (216) performed a retrospective review of 67 individuals who had received allo-HSCT 
containing T cells. They found that the rate of grade II–IV aGVHD in patients receiving statins 
was 10%, compared with 40% in non-treated group. Also the progression-free survival at three 
years in acute myeloid leukemia patients with or without statin use were 54 and 28%, 
respectively, which indicates the preserved GVL effect in patients using statins at the time of 
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allografting. Extensive preclinical and retrospective clinical data suggest that statins can prevent 
aGVHD without decreasing GVL effects. In order to prospectively validate these observations, 
phase-II clinical trials evaluating the role of Atorvastatin in preventing aGVHD is currently 
ongoing. The expected effects are to inhibit development of Th1 cells and enhance the induction 
of Th2 and Treg cells in GVHD patients (149, 217). 
 
1.6 Roles of CD8 T cells in GVHD development and mediating GVL effect  
T-cell alloreactivity is the key factor for the pathology of GVHD, and involves both 
helper CD4 and cytotoxic CD8 T-cell subsets. Unlike CD4 T cells that are activated by 
exogenous antigens presented by MHC-II molecules on recipient APCs, CD8 T cells are 
activated by endogenous antigens presented by MHC-I molecules. GVHD which developes 
across a full MHC disparity commonly requires both CD4 and CD8 T cells, with the dominant 
contribution of CD4 T cells and the additive pathology provided by CD8 T cells (218). GVHD 
can also develop even with matched MHCs but mismatched miHAs, where either CD8, or CD4 
T cells, or both are able to induce the disease, depending on the donor/recipient strain 
combinations (218). In MHC-mismatched systems, the GVHD target organ damages can occur 
without the direct interaction between cognate T cells and the MHC expressed on tissues, 
particularly in CD4-, to a lesser extent in CD8-, mediated GVHD which occurs at least partially 
as a result of cytokine production (219). However, in miHA-mismatched systems, CD8 but not 
CD4 T cells require TCR binding to MHC on target tissues in order to cause GVHD (220). Only 
host APCs are able to stimulate CD8 T cells to induce GVHD in CD8-dependent systems (221). 
Activated CD8 T cells will release perforin, granzymes and upregulate FasL to cause GVHD 
(222, 223).  
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In the aspect of mediating GVL effect, both CD4 and CD8 T cells require direct leukemic 
contact (220). Among various types of cells (NK cells, CD4 T cells and CD8 T cells) that are 
involved in GVL responses, CD8 T cells are considered as the major contributor due to their 
potent alloantigen specificity (224, 225) and cytolytic activity (226, 227). The helper CD4 T 
cells release cytokines and interact with APCs through costimulatory molecules and then 
stimulate those APCs. The activated APCs provide a “license to kill” to cytotoxic CD8 T cells, 
which is also important for the GVL effect (71). After donor CD8 T cells recognize the antigen 
expressed by the host malignant cells, either alloantigens or tumor-associated antigens, they will 
further lyse the target cells through similar mechanisms involved in GVHD, including the 
perforin-granzyme pathway alone, or  in combination with FasL-Fas pathway (228). Exposure 
and mobilization of lysosomal-associated membrane protrin-1 (LAMP-1/CD107a) during 
perfoin/granzyme-mediated lysis is well correlated with cytotoxic activity of CD8 T cells (229, 
230).  
 
1.7 Effect of APCs in GVHD and GVL 
APCs are essential to induce GVHD and mediate GVL reactions due to their ability to 
integrate and prime T cells. Multiple cell types from either the hematopoietic or 
nonhematopoietic compartments may participate in antigen presentation process with distinct 
efficiencies (231, 232).  
 
1.7.1 APCs populations 
1.7.1.1 Hematopoietic APCs. DCs, B cells, and macrophages are the major 
hematopoietic APCs that are also considered as the professional APCs with a specialized ability 
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to process and present antigens onto MHC molecules. These professional APCs have distinct 
circulatory patterns and occupy different locations. Conventional DCs can be divided into 
migratory DCs and resident DCs. Migratory DCs include the skin epidermal Langerhans cells 
and dermal DCs that uptake antigen from peripheral tissue and present it in the lymph nodes. 
Resident DCs, such as splenic or thymic DCs, load and process antigen within lymphoid organs 
(233, 234). Overall, DCs are the most effective APCs to prime T cells although depending on 
their origin and activation status. The activated conventional myeloid DCs can produce IL-12 
and promote Th1 differentiation, as well as cytotoxic CD8 T-cell responses (233). Naïve B cells 
recirculate between peripheral blood and secondary lymphoid organs without presenting in the 
skin or majority of the mucosal sites. They uptake antigens through B-cell receptor (BCR) and 
present on MHC-II molecules that interact with CD4 T cells, and generate efficient antibody 
responses (235).  Macrophages are strategically stationed at various locations throughout the 
body and perform their immune surveillance function. When danger signals such as tissue 
damage occur, they are actively recruited to the inflammatory sites and prepare to stimulate 
lymphocytes to combat pathogens (236).  
1.7.1.2 Nonhematopoietic APCs. Nonhematopoietic APCs include diverse types of 
cells, such as epithelial cells, endothelial cells and myofibroblasts, which can be induced to 
express MHC-II and develop antigen-presenting abilities under specific conditions. IFN-γ is the 
major effector cytokine to induce MHC-II expression both in vitro and in vivo, and likely enable 
those nonhematopoietic APCs to modulate either effector or memory CD4 T cell responses 
under inflammatory conditions (237). Nonhematopoietic APCs are distributed in different organs 
including the liver, intestine, and lung that are frequently targeted by allogeneic T cells during 
GVHD development (174, 237). 
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1.7.2 Pathways of antigen presentation after allo-HSCT 
There are two pathways of antigen presentation after allo-HSCT, direct presentation 
mediated by host APCs and indirect presentation mediated by donor APCs (238). Host 
alloantigens, either endogenous or exogenous, can be directly presented by host APCs to donor 
CD8 or CD4 T cells. Alternatively, host allogeneic MHC antigens or miHAs may be 
crosspresented by donor APCs to donor T cells.  Direct presentation is likely to be predominant 
during early stages of aGVHD, given that no GVHD was induced in mice lacking MHC-I on 
host APCs despite the capacity of donor APCs to perform cross-presentation (221).  However, 
indirect presentation driven by donor APCs may contribute to further tissue injury thus 
intensifying the aGVHD (239, 240). Moreover, CD4-dependent GVHD could be induced 
through either host or donor APCs (241), whereas only host APCs will initiate CD8-dependent 
GVHD (221). 
 
1.7.3 Effect of APCs in GVHD 
1.7.3.1 DCs in GVHD. After lethal conditioning, radiosensitive DCs and precursor cells 
derived from the host are lost within the first few days after allo-BMT. However, that period of 
time is long enough for host DCs to prime donor T-cell activation, and initiate their proliferation 
and differentiation. Studies show that host CD11c+ DCs were activated and accumulated in the T 
cell areas of the spleen within 6 hours of lethal irradiation. After 5 days, even though less than 
1% of host DCs were detectable, the primed donor CD8 T cells had undergone seven divisions 
which is sufficient to trigger GVHD in miHA-mismatched recipients (242). Adding back MHC-
II+/+ host-derived DCs, but not B cells, into MHC-II-/- mice could effectively break the resistance 
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of GVHD development in CD4-dependent model. Similar results were seen in CD8-dependent 
model although to a lesser extent (243). This demonstrates that host DCs rather than host B cells 
are critical in priming donor CD4 and CD8 T cells to induce GVHD. Moreover, persistence of 
host DCs is positively correlated with aGVHD (244, 245).  
After the first few days post-transplant, the vacancy in host APC numbers is filled by 
differentiated APCs contained within the donor graft or by other donor BM progenitor-
differentiated cells (238). Although the kinetics of full functional reconstitution are not clear, 
numerical recovery of DCs and macrophages has been shown to be more rapid than that of B 
cells (246). In preclinical murine BMT models, conventional DCs have been proved to be the 
critical donor APCs to induce GVHD, compared with macrophages or B cells (247). Clinical 
studies have documented that low numbers of circulating CD11c+ DCs in peripheral blood at the 
time of engraftment were associated with the increased risk for relapse, aGVHD and death aftter 
allo-HSCT, which may be explained by the increased DC homing to lymphoid tissues or GVHD 
target organs, and the lack of regulatory DCs (248). 
However, recent studies suggested that absence of recipient DCs using induced or 
constitutive depletion of CD11c+ conventional DCs exacerbates aGVHD when all other APC 
subsets are intact (249, 250). These findings have refined our understanding of APCs in GVHD, 
and warn against the strategies of simply targeting APCs especially DCs as a means to alleviate 
GVHD (233, 251). 
 
1.7.3.2 B cells in GVHD. The effect of B cells in aGVHD is still controversial. The 
effectiveness of B-cell depletion to reduce aGVHD in both mice (252) and humans (253-255) 
has demonstrated the pathogenic role of B cells, either donor-or host-derived. The timing of early 
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B-cell depletion by administrating rituximab seems crucial for its beneficical effects in aGVHD 
(256). In contrast, other studies have shown the protective effect of B cells. Host B cells, but not 
DCs within the spleen, are able to secret IL-10 after total body irradiation (TBI), thereby 
inhibiting the expansion of allogeneic T cells and the induction of aGVHD (257). Donor B cells 
have also been shown to alleviate aGVHD through a Treg-dependent mechanism (247, 258). 
1.7.3.3 Macrophages in GVHD. Similar to B cells, a consensus on the roles of 
macrophages in GVHD has not been reached. A study evaluating human sequential biopsy 
indicated that host macrophages contributed to GVHD through antigen presentation and cytokine 
production, leading to the activation and proliferation of CD8 T cells, and cytokine expression of 
memory CD4 T cells. The persistence of host macrophages is likely contributing to GVHD by 
maintaining the activated T-cell responses (259). However, a later study suggested that host 
macrophages which persist after conditioning can engulf donor alloreactive T cells and prevent 
their proliferation. As a result, preemptive CSF-1 therapy can ameliorate GVHD by expanding 
host suppressive or regulatory macrophages (260).  
1.7.3.4 Nonhematopoietic APCs in GVHD. Recent studies provide compelling evidence 
that hematopoietic APCs may not be essential for aGVHD induction, due to host 
nonhematopoietic APCs being sufficient to induce lethal aGVHD in mice (249, 250, 261). It has 
been known that nonhematopoietic cells could express MHC-II occasionally, such as within the 
gut and thymus (262, 263). The potential nonhematopoietic APCs that initiate GVHD include 
epithelial cells, endothelial cells and myofibroblasts, as suggested by different studies (249, 261). 
However, many aspects are still unknown regarding the mechanism of nonhematopoietic APCs 
to induce GVHD. For instance, where does the nonhematopoietic antigen presentation and 
alloactivation occur? Within the target tissues or in the context of stromal cells within secondary 
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lymphoid organs? Another possibility has been suggested by a recent study, where the donor 
DCs could incorporate the recipient MHC into their own membranes and indirectly mediate the 
nonhematopoietic antigen presentation (264). 
 
1.7.4 Roles of APCs in mediating GVL effect 
Both alloantigens and tumor-specific antigens (TSAs) can initiate GVL responses (70, 
265).  APCs are well known for inducing alloantigen-specific responses, demonstrating their 
importance for mediating GVL (266). Host APCs are predominated for full GVL effects, while 
donor APCs can also initiate GVL activity with low tumor bulk (239, 266). Given the host 
tumors express both alloantigens and TSAs, even if they perform antigen-presenting features, it 
is likely undergoing immune editing that results in ineffective T-cell response through multiple 
suppressive mechanisms (267). Recently, a subset of host–derived CD8+ DCs is suggested to 
play a critical role in enhancing TSA responses, and is required for optimal GVL effects (268). 
In the settings of delayed lymphocyte infusion (DLI), GVL can occur without GVHD (269). 
Here the GVL activity is dependent on MHC alloreactivity and little or no GVL activity against 
miHAs or TSAs is detected (269).  
 
1.7.5 Strategies to targeting APCs in allo-HSCT 
The strategies to manipulate the functions and/or numbers of APCs to achieve therapeutic 
benefit of allo-HSCT have been reported and are still under active investigation (233, 238, 270). 
Below is a summary of major interventional strategies on APCs, particular DCs, during 
experimental or clinical allo-HSCT (Table 1.2). 
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Table 1.2 Interventional strategies on APCs in allo-HSCT. 
Therapy Target Outcome Evidence Refs 
Alemtuzumab 
(Campath-1H) 
 
CD52+ DCs and T 
cells  
- Alloreactive 
stimulatory 
activity in vitro ↓ 
- Human aGVHD↓ 
- Depletion of CD52+ myeloid 
DCs from peripheral blood 
but not epidermis or gut. 
- Depletion of CD52+ T cells. 
 
(271) 
(272) 
(273) 
(274) 
(275) 
CMRF-44  
IgM Ab 
Langerhans cells 
(LC) and 
peripheral blood 
DC express 
CMRF-44 antigen  
- Number of 
migratory LC ↓ 
-Allostimulation 
by LC in vitro ↓ 
- Induces LC-depletion by 
complement-mediated 
cytotoxicity in vitro 
(276) 
Anti-CD83 
polyclonal Ab 
CD83+ activated 
DCs 
- Allogeneic T cell 
proliferation ↓ 
- aGVHD ↓ 
- GVL preserved 
- Induce lysis of activated 
CD83+ DCs. 
-Spare pre-existing donor T 
cells, including those target 
viruses and malignant cells. 
(251) 
IMMU-114 
mAb 
HLA-DR+ APCs 
(B cells, 
monocytes, DCs) 
- APCs apoptosis↑ 
- Alloreactive T-
cell proliferation ↓ 
 
- A humanized anti- HLA-DR 
mAb, efficiently deplete all 
APCs with little direct effect 
on T cells.  
(277) 
SAHA or 
ITF2357 
Histone 
deacetylase 
(HDAC) in DCs 
- Allostimulatory 
responses of DC ↓ 
- Murine aGVHD 
↓  
- GVL preserved 
- Reduce proinflammatory 
cytokine production, 
costimulatory molecule 
expression by DCs. 
- Increase expression of IDO. 
(278) 
Bortezomib Proteasome in 
immature DCs 
 
 
- Allogeneic T-cell 
proliferation ↓; 
Th1 ↓ 
- Immature DCs 
apoptosis ↑ 
- Murine or human 
aGVHD ↓  
- GVL preserved 
 
- Inhibit phenotypic and 
functional maturation and 
induce more potent apoptosis 
in immature DCs through 
suppression of NF-κB 
activity. 
- Decrease allogeneic T-cell 
proliferation and increase 
their apoptosis. 
(279) 
(280) 
(281) 
Regulatory 
DCs (rDCs) 
DC/T-cell 
interaction micro-
environment 
- Murine aGVHD 
and cGVHD↓  
- GVL preserved 
 
- rDCs displayed high levels 
of MHC molecules and 
extremely low levels of 
costimulatory molecules. 
- Generation of donor 
inducible Tregs and anergic, 
Ag-specific CD4+ T cells. 
(282) 
(283) 
(284) 
Genetically 
modified 
Trail-DCs 
DC/T-cell 
interaction micro-
environment 
- Murine aGVHD 
↓  
- GVL preserved 
- Induce alloreactive T-cell 
and tumor-cell apoptosis 
through Trail-DR5 pathway. 
(285) 
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Chapter 2: T-bet is Critical for the Development of Acute Graft-versus-Host Disease 
through Controlling T cell Differentiation and Function2 
 
2.1 Abstract 
T-bet is a master regulator for IFN-γ production and Th1 differentiation. We evaluated 
the roles of T-bet and IFN-γ in T cell responses in acute GVHD and found that T-bet-/- T cells 
induced significantly less GVHD compared with wild-type or IFN-γ-/- counterparts in both MHC-
mismatched and MHC-matched but miHA–mismatched models driven by CD4 T cells. T-bet-/-, 
but not IFN-γ-/-, CD4 T cells had a markedly reduced ability to cause tissue damage in liver and 
gut. This distinct outcome is reflected by the differential gene expression on donor CD4 T cells 
deficient for T-bet or IFN-γ. At mRNA and protein levels, we defined several T-bet-dependent 
molecules that may account for the impaired ability of T-bet-/- T cells to migrate into target 
organs and to produce Th1-related cytokines. Moreover, these molecules were independent of 
either endogenous IFN-γ, such as CXCR3 and programmed death-1 (PD-1), or systematic IFN-γ, 
such as NKG2D, I-Ab, and granzyme B (GZMB). Although both T-bet-/- and IFN-γ-/- CD4 T 
cells are prone to differentiate into Th17 cells, polarized Th17 cells deficient for T-bet but not for 
IFN-γ had a significantly reduced ability to cause GVHD. Finally, T-bet-/- T cells had a 
compromised GVL effect, which could be essentially reversed by neutralization of IL-17 in the 
recipients. We conclude that T-bet is required for Th1 differentiation and migration, as well as 
                                                      
2
 This chapter have been previously published (Fu et al. J Immunol. 2015 Jan 1;194(1):388-97.) 
and are utilized with permission of the publisher (p131). 
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for optimal function of Th17 cells. Thus, targeting T-bet or regulating its downstream effectors 
independent of IFN-γ may be a promising strategy to control GVHD in the clinic. 
 
2.2 Introduction 
GVHD is a major limitation for the efficacy of allo-HSCT in the treatment of 
hematologic malignancies because it leads to significant morbidity and mortality (63). The 
cytokine storm caused by conditioning and Th1-cell cytokines produced by allogeneic T cells are 
the driving forces for the initiation and development of GVHD (78, 152, 153, 286). 
Paradoxically, the principal Th1 cytokine, IFN- γ, plays a dispensable role for GVHD 
development in some experimental murine BMT models (154-157, 287, 288), where exacerbated 
GVHD was observed in hosts receiving IFN-γ-/- grafts (155, 157, 287, 288) or after IFN-γ 
neutralization (287) following lethal irradiation.  On the other hand, administration of 
recombinant IFN-γ showed a protective effect for CD4 T-cell mediated GVHD (154) .  
 
T-bet, the T-box transcription factor, has a unique role in the differentiation of all three 
subsets (Th1, Th2, Th17) of CD4+ helper T cells by promoting Th1 differentiation, while 
simultaneously inhibiting Th2 and Th17 lineage commitment (24). T-bet target genes have been 
identified in primary human T cells, which show that T-bet is associated with genes of various 
functions in Th1 cells, including those with roles in transcriptional regulation, chemotaxis, and 
adhesion (117). T-bet is a transcriptional activator of IFN-γ (1) and orchestrates the cell-
migratory program by directly controlling expression of the chemokine receptors CXCR3 and 
CCR5, as well as the chemokines CCL3 and CCL4 (117, 118). T-bet also has cooperative and 
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partially redundant functions with Eomes, another T-box transcription factor, to control CD8 T 
cell cytotoxicity and IFN-γ production (32, 33). 
 
Previously, we observed that T cells deficient for T-bet are impaired in the induction of 
acute GVHD (47). However, the effect and mechanism of T-bet on T cells to induce GVHD and 
mediate the GVL effect has not been thoroughly studied, particularly the reason for the 
paradoxical outcomes of GVHD caused by T-bet-/- or IFN-γ-/- T cells. We therefore utilized T 
cells from T-bet-/- or IFN-γ-/- mice as donors and tested whether T-bet could be a potential target 
for preventing GVHD after allo-BMT. We then elucidated the underlying mechanisms by which 
T-bet or IFN-γ differentially regulates allogeneic T-cell response after allo-BMT. We identified 
several molecules that depend on T-bet, but not on endogenous IFN-γ produced by donor T cells 
or systematic IFN-γ produced by any type of cell, which may be responsible for T-cell 
pathogenicity in GVHD induction. Furthermore, we define the role of T-bet in Th17 function 
related to GVHD and its impact on the GVL effect. Our study provides new biological insight on 
T-bet, as well as the rationale to target T-bet or its downstream effectors, to control GVHD after 
allo-BMT.   
 
2.3 Materials and methods 
 
2.3.1 Mice 
C57BL/6 (B6; H-2b, CD45.2), B6.Ly5.1 (CD45.1) and BALB/c (H-2d) were purchased 
from National Cancer Institute (NCI, Frederick, MD). T-bet-/-, IFN-γ-/- and IFN-γR-/- mice on B6 
background and founders of C.B10-H2b/LilMcdJ (BALB.B; H-2b) mice were purchased from 
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The Jackson Laboratory (Bar Harbor, ME). BALB.B mice were bred at H. Lee Moffitt Cancer 
Center (Moffitt, Tampa, FL). All animals were housed in the American Association for 
Laboratory Animal Care–accredited Animal Resource Center at Moffitt or Medical University of 
South Carolina (MUSC, Charleston, SC). Experiments were carried out under protocols 
approved by the Institutional Animal Care and Use Committee of University of South Florida 
(Tampa, FL) or MUSC. 
 
2.3.2 BMT models 
T-cell purification from whole spleen and lymph nodes was done by negative depletion 
using magnetic beads as previously described (47). MHC- and miHA-mismatched 
(B6→BALB/c) or MHC-matched but miHA-mismatched (B6→BALB.B) BMT models were 
used as previously established (289). Briefly, 8-10 week old recipient mice were conditioned 
with total body irradiation (TBI) based on weight at 750 to 850 cGy (single dose) for BALB/c 
and 900 to 950 cGy (split 3 hours apart) for BALB.B using a Shepherd Mark I Cesium Irradiator 
(J. L. Shepherd and Associates, San Fernando, CA) at Moffitt, or at 650 to 750 cGy (single dose) 
for BALB/c using an X-RAD 320 X-ray Irradiator (Precision X-ray Inc., North Branford, CT) at 
MUSC. Within 24 hours post-conditioning, recipients were intravenously injected with T-cell 
depleted (TCD) BM alone with or without T cells from different strains of donors. Recipient 
mice were monitored for weight loss and other clinical signs of GVHD twice/week.  Clinical 
scores were tabulated as 5 parameters: weight loss, posture, activity, fur texture, and skin 
integrity. Individual mice were scored 0 to 2 for each criteria and 0 to 10 overall (290). A GVL 
model was established by intravenously injecting luc/neo plasmid-transduced A20 B-cell 
lymphoma cells (A20-luc) on BALB/c background the day of BMT (2×103 A20 cells/mouse).  In 
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addition, recipients were treated with anti-IL-17 mAb (clone: 17F3; Bio X Cell, West Lebanon, 
NH) or PBS control at doses and schedules specified. Tumor growth was measured with 
bioluminescent imaging (BLI) using Xenogen-IVIS ® 200 Pre-clinical In vivo Imaging System 
(Perkin-Elmer, Waltham, MA) and analyzed by Living Image Software (Perkin-Elmer) as 
previously described (291).  Tumor and GVHD mortality were distinguished by BLI signal 
intensity and clinical manifestation of GVHD.  Recipients at pre-moribund stage were 
euthanized and counted for lethality. Representative samples of GVHD target organs were 
excised from recipients 14 days post-BMT and subjected to pathology scoring as previously 
described (47, 291). 
 
2.3.3 Flow cytometry and serum cytokine detection 
Mononuclear cells were isolated from recipient spleen or liver as previously described 
(47, 291, 292) and stained for surface receptors and intracellular cytokines using standard flow 
cytometric protocols. Stained cells were analyzed using Diva software, LSR II (BD Biosciences, 
San Jose, CA), and FlowJo (TreeStar, Ashland, OR). Cytokine levels in recipient serum were 
quantified using a cytometric bead assay (BD Biosciences, San Jose, CA) (293). 
 
2.3.4 Microarray and real-time PCR 
Lethally irradiated BALB/c mice were transplanted with WT Ly5.1+ B6 TCD-BM (5 × 
106/mouse) plus WT, T-bet-/- or IFN-γ-/- naïve CD4+ Ly5.1- T cells (1 × 106/mouse). Recipients 
were euthanized on day 7. Donor-derived T cells (CD4+ H-2Kb+ Ly5.1- DAPI-) in recipient 
splenocytes were isolated by cell sorting (BD FACSAria II Cell Sorter), and lysed in TRIzol 
(Life technologies, Grand Island, NY) to extract total RNAs. Microarray analysis was performed 
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using GeneChip Mouse Genome 430 2.0 arrays (Affymetrix, Santa Clara, CA). Array images 
were analyzed and processed by robust multi-array average (RMA) procedure (294, 295). Heat 
map was generated by using Cluster 3.0 and Java TreeView. In order to identify potential genes 
significantly changed (either increased or decreased) in the T-bet-/- versus WT group, but not 
shared by the IFN-γ-/- group, three sets of genes were selected: 1) signal fold change of T-bet-/- 
vs. WT >2; 2) signal fold change of T-bet-/- vs. IFN-γ-/- >2; and 3) signal fold change of IFN-γ-/- 
vs. WT >2. Fold change calculation was based on the mean value of individual values from three 
independent experiments. The genes overlapped in set 1 and set 2 were further selected, and 
genes from set 3 were excluded from those selected genes. The signal value below 500 is 
considered as background noise. Thus, the primary pool of T-bet-dependent but endogenous 
IFN-γ-independent genes was established. Additional criteria were added when heat map 
analysis was performed. When selecting T-bet positively regulated genes, the signal fold change 
of T-bet-/- vs. WT, T-bet-/- vs. IFN-γ-/-, and IFN-γ-/- vs. WT is >4, >3 and <2, respectively, and the 
lowest signal value limit of WT group is set at 1675 (210.71). When selecting T-bet negatively 
regulated genes, the signal fold change of T-bet-/- vs. WT, T-bet-/- vs. IFN-γ-/-, and IFN-γ-/- vs. 
WT is >2, >2 and <2, respectively, and the lowest signal value limit of T-bet-/- group is set at 
1024 (210). In heat map scale, signal value of 1024 (210) was termed “0.00” and represented by 
black color; signal value of 8192 (213) was termed “3.00” and represented by red color; signal 
value of 128 (27) was termed “-3.00” and represented by green color. Mouse array data can be 
accessed at ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) under accession number E-
MTAB-2198.  
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To quantify mRNA using real-time PCR, extracted total RNA was reverse transcribed to 
cDNA using a High Capacity cDNA Reverse Transcription Kit. All PCR experiments were 
performed using TaqMan gene expression assays (Hopx, Mm00558630_m1; Slamf1, 
Mm00443316_m1; Serpinb9, Mm00777163_m1; Igf2r, Mm00439576_m1; Klrd1, 
Mm00495182_m1; Klrc1, Mm00516111_m1; H-2Aa, Mm00439211_m1; H-2Ab1, 
Mm00439216_m1; Retnla, Mm00445109_m1; GAPDH, Mm99999915_g1), universal PCR 
Master Mix and the ABI-PRISM 7900 Sequence Detection System (Applied Biosystems, Life 
technologies, Grand Island, NY). Target gene expression was calculated using the comparative 
method for relative quantitation upon normalization to the internal GAPDH expression control. 
 
2.3.5 In vitro generation of Th17 cells and Th17-mediated GVHD model 
CD4+CD25- cells isolated from WT, T-bet-/- or IFN-γ-/- mice on B6 background were 
stimulated in the presence of syngeneic APCs with 2 μg/mL anti-CD3 mAb, 5 ng/mL TGFβ, 10 
ng/mL IL-6 and 5 μg/mL anti-IFN-γ mAb. On day 3, 50U/mL mIL-2 was added. Cell phenotype 
(CD4+ IL-17+ %) was confirmed on day 4 by intracellular cytokine staining of IFN-γ and IL-17.  
On day 5, polarized T cells were collected and dead cells were removed using Ficoll separation. 
Equal numbers of live CD4+ IL-17+ cells derived from WT, T-bet-/- or IFN-γ-/- T cells were used 
to induce GVHD to compare pathogenicity.    
 
2.3.6 Statistics 
For comparison of recipient survival among groups in GVHD experiments, the log-rank 
test was used to determine statistical significance. To compare GVHD clinical scores, pathology 
scores, weight loss, cytokine levels, and gene expression levels, a Student t test was used. 
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2.4 Results 
 
2.4.1 T-bet is required for CD4 T-cell mediated acute GVHD 
Our previous study indicated that T-bet-/- total T cells are less pathogenic than their WT 
counterparts in inducing GVHD in fully MHC-mismatched BMT models (47). In contrast, IFN-
γ, a major cytokine regulated by T-bet, is dispensable or even protective against GVHD 
development (154-157, 287, 288).  Considering Eomes is preferentially expressed on CD8 T 
cells (32, 37) and CD4 T-cell differentiation is better defined (286, 296), we first focused our 
studies on CD4-mediated GVHD and aimed to further understand how T-bet and IFN-γ 
differentially affect the development of acute GVHD.  As shown in figure 2.1, IFN-γ-/- CD4 T 
cells mediated comparable GVHD to WT CD4 T cells, whereas T-bet-/- CD4 T cells caused 
significantly milder GVHD. Recipients of T-bet-/- donor T cells showed significantly higher 
long-term survival rates (Figure 2.1A), less weight loss (Figure 2.1B) and lower GVHD clinical 
scores after 4 and 8 weeks following allo-BMT (Figure 2.1, C and D) compared with the 
recipients of either WT or IFN-γ-/- CD4 T cells. Alleviated GVHD caused by T-bet-/- CD4 T cells 
was also supported by significantly lower pathological scores of those recipients 14 days after 
allo-BMT. Recipients of T-bet-/- CD4 T cells had markedly reduced T-cell infiltration and tissue 
damage in GVHD target organs including the liver, gut, and skin (Figure 2.1, E and F). However, 
T-bet-/- CD4 T cells induced similar severity of pulmonary GVHD as WT CD4 T cells (Figure 
2.1, E and F), consistent with the previous report that pulmonary GVHD is not associated with 
Th1-mediated response (297). Serum cytokines detected 14 days post-transplant revealed that T-
bet-/- CD4 T cells produced significantly lower levels of IFN-γ compared to WT CD4 T cells  
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Figure 2.1 T-bet is required for CD4 T-cell mediated acute GVHD. Lethally irradiated BALB/c 
mice were transplanted with 5×106/mouse TCD-BM from WT B6 donor alone (n=7), or plus WT 
(n=10), T-bet-/- (n=11), or IFN-γ-/- (n=10) CD4+ T cells at 1×106/mouse. Recipient mice were 
monitored throughout the experimental period for survival (A), weight change (B), GVHD 
clinical scores at 4 weeks (C) and 8 weeks (D) post-transplant. Lethally irradiated BALB/c mice 
were transplanted with 5×106/mouse TCD-BM from WT B6 donor alone (n=4), or plus WT 
(n=7), T-bet-/- (n=7), or IFN-γ-/- (n=8) naïve CD4+ T cells at 1×106/mouse. Recipients were 
euthanized 14 days post-transplant and samples of liver, lung, small intestine, colon and skin 
were collected for H&E staining (E) and scored for microscopic GVHD severity by a pathologist 
blinded to the treatment groups. Photomicrographs depicting the average disease score 
morphology from one representative experiment out of two separate experiments (Original 
magnification ×200).  Pathological score mean ± SE (F) of GVHD target organs across two 
separate experiments are depicted. Sera collected at necropsy 14 days post-transplant were 
subjected to cytokine bead analysis (G) to quantify serum cytokine concentrations of IFN-γ, 
TNF-α, IL-6, and IL-10. Cytokines that were undetectable are not graphically represented. (H) 
Recipients were euthanized 14 days post-transplant and samples of spleen and liver were 
collected for intracellular staining of IL-17. FACS plots show CD4+IL-17+ cells from 
representative recipients in each group. Data are shown from two replicate experiments 
combined. Asterisk indicates statistical significance: *p<0.05, **p<0.01, ***p<0.001.  
 
 (Figure 2.1G). Consistent with the pathological scores, T-bet-/- CD4 T cells also produced lower 
levels of TNF-α, but higher levels of IL-10 and IL-6 compared to either WT or IFN-γ-/- CD4 T 
cells (Figure 2.1G). Furthermore, intracellular IL-17 expression was significantly higher in T-bet-
/- or IFN-γ-/- donor T cells than in WT donor T cells in recipient spleens and livers (Figure 2.1H).  
Altogether, T-bet deficient CD4 T cells produced lower levels of inflammatory cytokines and 
induced less damage in the recipient liver, gut and skin, indicating that T-bet, not IFN-γ, is 
required for CD4 T-cell mediated acute GVHD. 
 
2.4.2 T-bet is important for GVHD induction in miHA-mismatched model 
miHA mismatches play a critical role in clinical GVHD development in human leukocyte 
antigen (HLA)-identical BMT conditions (298). Given the effect of T-bet-/- or IFN-γ-/- total T 
cells in fully MHC-mismatched models has been reported previously by us and others (47, 288, 
299), we utilized a clinically relevant MHC-matched, multiple miHA-mismatched CD4-
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dependent BMT model, B6→BALB.B, and found that the recipients which received splenocytes 
from T-bet-/- mice demonstrated prolonged survival with decreased GVHD severity compared 
with those that received WT or IFN-γ-/- splenocytes (Figure 2.2). These results suggested that T-
bet plays a critical role in the development of acute GVHD regardless of BMT model. 
 
 
 
Figure 2.2 T-bet is required for GVHD induction in miHA-mismatched BMT model. 
Lethally irradiated BALB.B mice were transplanted with 5×106/mouse TCD-BM from WT B6 
donor alone (n=6), or plus WT (n=9), T-bet-/- (n=11), or IFN-γ-/- (n=9) splenocytes (SP) at 
20×106/mouse. Recipient mice were monitored throughout the experimental period for survival 
(A) and weight change (B).  Data are shown from two replicate experiments combined. Asterisk 
indicates statistical significance: *p<0.05, **p<0.01, ***p<0.001.  
 
2.4.3 Differential gene profiles of T-bet-/- and IFN-γ-/- CD4 T cells after allo-BMT 
To determine the mechanism of how T-bet affects T-cell pathogenicity in the induction of 
GVHD, we hypothesized that the molecules which are regulated by T-bet but not required for 
IFN-γ production are responsible for GVHD development.  To identify these molecules, we 
isolated donor CD4 T cells from spleens of recipients at 7 days following allo-BMT 
(B6→BALB/c) and analyzed the gene profiles by microarray.  Internal controls, Tbx21 (gene 
encoding T-bet) and Ifng (gene encoding IFN-γ), were essentially absent in T-bet-/- CD4 T cells 
and IFN-γ-/- CD4 T cells, respectively (Figure 2.3, A and B).  The microarray heat map showed  
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that, a total of 28 genes were down-regulated and 8 genes were up-regulated only in T-bet-/- but 
not in IFN-γ-/- CD4 T cells compared to WT CD4 T cells (Figure 2.3A).  Among them, we chose 
to present those genes potentially relevant to GVHD in a bar graph, including Cxcr3, Ccr5, Ccl3, 
Ccl4, Klrc1, Klrd1, Nkg7, and Pdcd1 that were positively regulated, whereas H2-Aa and H2-Ab1 
were negatively regulated by T-bet independent of endogenous IFN-γ (Figure 2.3B).  Changes in 
representative genes (Hopx, Slamf1, Serpinb9, Igf2r, Klrd1, Klrc1, H2-Aa, H2-Ab1 and Retnla) 
were confirmed by real time PCR (Figure 2.3C).  We reason that at least some of those genes we 
identified are responsible for the compromised ability of T-bet-/-, not IFN-γ-/-, CD4 T cells in the 
induction of GVHD. 
 
 
Figure 2.3 Differential gene profiles of T-bet-/- and IFN-γ-/- CD4 T cells after allo-BMT. 
Lethally irradiated BALB/c mice were transplanted with 5×106/mouse TCD-BM from WT 
Ly5.1+ B6 donor plus WT, T-bet-/- or IFN-γ-/- naïve CD4+ Ly5.1- T cells at 1×106/mouse (n=4 per 
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group per experiment). Recipients were euthanized 7 days post-transplant and their spleens were 
collected. By sorting different strains of donor-derived T cells (CD4+ H-2Kb+ Ly5.1- DAPI-) 
from recipient splenocytes, 1~2×106 cells were obtained per group, and total RNAs were 
extracted for microarray and real-time PCR analysis. The genes shown are significantly changed 
in the T-bet-/- group but not shared by the IFN-γ-/- group. Heat map (A), and mean signal value ± 
SE (B) of representative genes identified by microarray using either WT, T-bet-/-, or IFN-γ-/- 
donor CD4 T cells were shown. Selected gene expressions were confirmed by real-time PCR 
(C). Pooled data from three independent experiments are presented. Asterisk indicates statistical 
significance: **p<0.01, ***p<0.001.    
 
2.4.4 T-bet regulates T-cell pathogenicity through IFN-γ-independent manners 
Our microarray data provides potential explanations for why T-bet-/- and IFN-γ-/- T cells 
induce distinct outcomes of GVHD at the gene level. However, protein expression is typically 
better correlated with biological function. To confirm our microarray study and further 
investigate the underlying mechanism, we utilized a MHC-mismatched BMT model 
(B6→BALB/c), and examined the expression of several molecules, which represent multiple 
aspects of allogeneic T-cell function: activation (I-Ab and NKG2D), migration (CXCR3), 
cytotoxicity (CD94 and GZMB), and exhaustion (PD-1), of donor T cells by flow cytometry 7 
days after allo-BMT.  We observed that T-bet-/- donor T cells significantly impaired proliferation 
in secondary lymphoid organs (spleen) and migration into target organs (liver), when compared 
to their WT counterparts (Figure 2.4A). This was consistent with their significantly decreased 
IFN-γ production, but increased IL-17 and IL-10 secretion (Figure 2.4B). T-bet-/- donor T cells 
also showed significantly less infiltration into the liver compared with IFN-γ-/- T cells (Figure 
2.4A). The expansion defect of T-bet-/- T cells in the spleen is mostly displayed in the CD8 but 
not CD4 subpopulation (Figure 2.4A), which indicated that absence of T-bet affects multiple 
aspects of CD4 T cell function independent of cell expansion. Moreover, in contrast to WT or 
IFN-γ-/- T cells, T-bet-/- T cells significantly decreased the expression of CXCR3, NKG2D, PD-1, 
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and CD94, but increased the expression of I-Ab and GZMB in CD4 or CD8 constituent 
subpopulations (Table 2.1), or both (Figure 2.4C). 
 
 
Figure 2.4 T-bet regulates T-cell migration and cytokine production through IFN-γ-independent 
manners. Lethally irradiated BALB/c mice were transplanted with 5×106/mouse TCD-BM from 
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WT Ly5.1+ B6 donor plus WT, T-bet-/-, IFN-γ-/- or IFN-γR-/- naïve CD4+ Ly5.1- T cells at 
1×106/mouse (n=3~4 per group). Recipients were euthanized 7 days post-transplant and their 
spleens and livers were collected and absolute numbers of donor total T cell, CD4+ or CD8+ T 
cell were shown (A). Production of IFN-γ, IL-17 and IL-10, and expression of CXCR3, NKG2D, 
I-Ab, PD-1, CD94 and granzyme B (GZMB) by WT, T-bet-/-, IFN-γ-/- or IFN-γR-/- donor T cell in 
recipient spleen were shown in bar graph (B), and histograms (C), respectively. Data from one 
representative experiment were presented. Asterisk indicates statistical significance: *p<0.05, 
**p<0.01, ***p<0.001. 
 
Table 2.1 Differential protein expression of T-bet-/- and IFN-γ-/- T cell after allo-BMT.            
Mean ± 
SD % 
CD4
+
  CD8
+
  
WT T-bet
-/-
  IFN-γ
-/-
  IFN-γR
-/-
 
 
WT T-bet
-/-
  IFN-γ
-/-
  IFN-γR
-/-
 
CXCR3 44.9±8.6 30.2±3.0 57.5±4.3 24.2±2.0 
 
73.6±6.1 48.0±3.4 80.3±3.6 56.8±1.0 
NKG2D 22.1±0.7 20.9±2.1 18.8±1.5 14.9±0.5 
 
60.9±1.5 29.3±2.0 47.7±2.3 52.4±4.9 
I-A
b
 17.1±3.7 54.6±9.1 15.2±3.5 26.9±3.4 
 
29.7±4.6 55.8±4.1 25.7±5.5 37.0±4.9 
PD-1 15.5±2.5 12.0±1.8 17.0±4.5 5.9±1.0 
 
43.4±5.7 30.9±3.0 62.3±7.3 24.3±5.4 
CD94 10.3±0.8 2.4±1.3 3.3±0.8 2.6±1.3 
 
26.4±0.8 4.9±1.1 35.6±3.6 34.0±5.7 
GZMB 1.6±0.6 6.3±2.9 1.8±1.0 2.0±0.4 
 
0.6±0.4 3.0±2.1 1.3±0.3 0.5±0.3 
     
Given IFN-γ can be produced by other cell types besides donor T cells, we aimed to 
distinguish the dependence of endogenous or systematic IFN-γ by including IFN-γR-/- T cells as 
additional controls, which are able to produce IFN-γ (Figure 2.4B) but unable to respond to IFN-
γ. We found that CXCR3 and PD-1 were expressed in similarly low levels on the T cells 
deficient for T-bet or IFN-γR, but not IFN-γ. This suggests that their protein expression depends 
on T-bet, not endogenous IFN-γ, although it can be regulated by IFN-γ produced by other types 
of cells in the recipient. On the other hand, the expression of NKG2D, CD94, I-Ab and GZMB 
depends on T-bet, but not systematic IFN-γ, because their protein profiles are distinct on the T 
cells deficient for T-bet versus either IFN-γ or IFN-γR. Therefore, we have identified several T-
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bet-dependent, but endogenous or systematic IFN-γ-independent molecules, that likely 
contributed to the impaired target organ migration and Th1-cytokine production by T-bet-/- T 
cells.  
  
2.4.5 T-bet controls the optimal function of Th17 cells in GVHD induction 
It is known that Th1-differentiation antagonizes Th17-differentiation (30, 300). Our data 
shows that either T-bet-/- or IFN-γ-/- T cells are prone to differentiate into Th17 cells both in vitro 
(Figure 2.5) and in vivo (Figure 2.1H), which is consistent with previous reports (47, 159).   
 
 
Figure 2.5 T-cell differentiation from WT, T-bet-/- and IFN-γ-/- CD4 T cells in vitro. Isolated 
CD4+ CD25- T cells (5×105) from WT, T-bet-/-, and IFN-γ-/- mice on B6 background were co-
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cultured with enriched CD11chigh (5×104) allogeneic bone marrow-derived dendritic cells (BM-
DCs) for 5 days and the difference in IFN-γ and IL-17 production were shown by FACS plots.  
 
Given the Th17 subset, per se, is capable of causing GVHD (80, 81), we hypothesized that 
optimal activity of Th17 cells may require T-bet but not IFN-γ, which may attribute to a distinct 
pathogenicity of T-bet versus IFN-γ in GVHD induction. Therefore, we examined the role of T-
bet or IFN-γ in the pathogenicity of Th17 cells to cause GVHD using optimized Th17-polarizing 
culture conditions. We generated > 70% CD4+ IL-17+ cells from naïve CD4 T cells of WT, T-
bet-/- or IFN-γ-/- B6 mice (Figure 2.6A) and then transferred equal numbers of these T cells into 
lethally irradiated BALB/c recipients. We found that T-bet-/-, not IFN-γ-/-, Th17 cells had a 
significantly reduced ability to induce GVHD. This is reflected by ameliorated morbidity and 
mortality of the recipients (Figure 2.6, B and C). Because bone marrow stromal niche is 
considered a sensitive target of allogeneic T cells, and the defective donor bone marrow-derived 
B lymphopoiesis is correlated with GVHD severity (301), we examined the percentage of donor-
derived B cells at the end of observation periods (around day 85 after allo-BMT), which was 
found to be significantly higher in the recipients of T-bet-/- Th17 cells than those of WT or IFN-γ-
/- Th17 cells (Figure 2.6 E), despite a similar number of total splenocytes among these groups 
(Figure 2.6 D). These data strongly suggest that T-bet also affects the pathogenicity of Th17 cells 
in GVHD induction. Moreover, Th17 pathogenic and nonpathogenic signature molecules are 
previously defined in autoimmune models, such as experimental autoimmune encephalomyelitis 
(EAE) (302-304). Based on the similar requirement of Th1 and/or Th17 cells and on T-bet 
expression in the induction of EAE and GVHD (47, 49), we used the genes identified in EAE 
model as a reference, to indirectly reflect the effects of T-bet on regulating Th17 pathogenicity in 
allo-BMT settings. Our microarray results indicate that T-bet positively regulated Th17 
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pathogenic signature genes on CD4 T cells after allo-BMT, such as Lrmp, Ccl5, ICOS, Stat4, 
Lgals3, Malt1 and GM-CSF, while negatively regulating Th17 nonpathogenic signature genes 
such as IL-10 (Figure 2.7).  The observation is in-line with our hypothesis that T-bet contributes 
to the optimal function of Th17 cells after allo-BMT.  
 
 
Figure 2.6 T-bet controls the optimal function of Th17 cells in GVHD induction. Lethally 
irradiated BALB/c mice were transplanted with 5×106/mouse TCD-BM from WT B6 donor 
alone (n=8), or plus in vitro polarized WT (n=12), T-bet-/- (n=17) or IFN-γ-/- (n=12) Th17 cells 
(A) at 0.5~1×106 /mouse after normalization of IL-17 producing CD4+ cells. Recipient mice 
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were monitored throughout the experimental period for survival (B) and weight change (C). 
Upon completion of the experiment on day 80-90, absolute number (D) and percentage of donor-
derived B-cell (B220+) and T-cell (CD4+ or CD8+) reconstitution (E) of the spleen cells from 
remaining recipients were analyzed. Pooled data from three independent experiments are 
presented. Asterisk indicates statistical significance: *p<0.05, **p<0.01, ***p<0.001.  
 
 
Figure 2.7 T-bet regulates Th17 pathogenic or nonpathogenic signature genes after allo-BMT. 
Mean signal value ± SE of selected Th17 pathogenic or nonpathogenic genes including Lrmp, 
Ccl5, ICOS, Stat4, Lgals3, Malt1, GM-CSF and IL-10, identified by microarray using either WT, 
T-bet-/-, or IFN-γ-/- donor CD4 T cells 7 days post allo-BMT were shown. Pooled data from three 
independent experiments are presented. Asterisk indicates statistical significance: *p<0.05, 
**p<0.01, ***p<0.001.  
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2.4.6 T-bet-/- donor T cells largely preserve the GVL effect by neutralizing IL-17 in 
allo-BMT recipients 
The ultimate goal of allo-HSCT is to prevent GVHD while preserving the GVL effect. 
Cytotoxic CD8 T cells are known to play a predominate role in mediating GVL effects (265, 
305). GVL effects of IFN-γ-/- T cells have been shown to correlate inversely with their GVHD-
inducing activity in a CD8-dependent model (157).  We hypothesized that T-bet-/- T cells may 
maintain their GVL activity due to the presence of Eomes, which preserves CD8 T-cell cytotoxic 
activity (32, 33).  We tested the expression of Eomes and IFN-γ on CD4 and CD8 T cells in the 
presence or absence of T-bet and found that Eomes was mainly expressed on CD8 T cells 
compared to CD4 T cells.  T-bet-/- CD8 T cells highly expressed Eomes and maintained IFN-γ 
production (Figure 2.8).  To determine whether T-bet is required for T-cell mediated GVL effect, 
we used a B6 → BALB/c BMT model and infused a low dose of A20-luc B-cell lymphoma on 
the day of allo-BMT, which mimics clinical setting where a small number of malignant cells 
survive in patients after pre-conditioning regimen.  We found that WT T cells at 0.25~0.5 × 
106/mouse could effectively reject tumor, but the majority of recipients (79%) quickly died of 
GVHD (Figure 2.9 A, B and C).  However, the recipients of 0.25~0.5 × 106 T-bet-/- T cells 
showed delayed tumor growth compared to those of BM alone, but eventually the majority of 
these recipients (86%) died of tumor relapse (Figure 2.9 A, B and C).  These data suggest that 
although T-bet deficient T cells still express Eomes and had partially preserved ability to produce 
IFN-γ, their GVL activity was largely compromised.  
T cells deficient for T-bet produce elevated levels of IL-17 (Figure 2.1H and 2.4B). 
Substantial evidence supports that IL-17 enhances tumor resistance to anti-angiogenesis therapy 
(306), promoting tumor progression through an IL-6/Stat3 signaling pathway (307, 308).  Our 
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previous study indicates that additional RORγt (transcription factor of Th17 cells) deficiency 
reverses the enhanced ability of T-bet-deficient T cells to produce IL-17. Furthermore, T-
bet/RORγt-deficient T cells have largely preserved GVL activity (47).  Therefore, we further 
hypothesized that elevated IL-17 contributed to the compromised GVL effect of T-bet-/- T cells. 
To test this, we used the same MHC-mismatched B6→BALB/c model with IL-17 neutralizing 
mAb (clone: 17F3), and found that treatment with anti-IL-17 mAb significantly reduced tumor 
relapse in the recipients of T-bet-/- T cells. This is reflected by improved survival (Figure 2.9A) 
and reduction of tumor signal intensity by BLI (Figure 2.9 C and D).   In contrast, the same 
treatment did not affect the survival of the recipients transplanted with WT T cells.  Our data 
suggests that the compromised GVL activity of T-bet-/- T cells was, at least in part, due to 
elevated IL-17 produced by these T cells.  
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Figure 2.8 T-bet and Eomes expression on WT, T-bet-/- and IFN-γ-/- T cells in vitro. WT, T-bet-/- 
or IFN-γ -/- splenocytes were harvested and stimulated with anti-CD3 Ab for 3 days. PMA and 
ionomycin were added on day 3 to further stimulate the cells for intracellular staining of IFN-γ. 
Expression of T-bet, Eomes and production of IFN-γ by CD4 or CD8 T cells were shown.   
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Figure 2.9 T-bet-/- donor T cells largely preserve GVL effect upon neutralizing IL-17 in allo-
BMT recipients. BALB/c mice were lethally irradiated and transplanted with 5×106/mouse TCD-
BM from WT B6 donor alone, or plus WT or T-bet-/- purified T cells at 0.25~0.5×106/mouse. 
Additionally, recipients were intravenously injected with 2×103/mouse A20 luciferase-
transduced lymphoma cells at the time of BMT. Recipients were i.p. injected with α-IL-17 mAb 
(500μg/mouse for first dose, and 200μg/mouse for the following doses) or PBS control for 4 
weeks (at day 0, 3, 7, 10, 14, 18, 21, 25 and 28), and were monitored throughout the 
experimental period for survival (A), weight change (B), and tumor growth by luciferin i.p. 
injection and whole body BLI (n=4~7 per group per experiment). Recipient BLI image (C) 
represents one of the 2 replicated experiments and average radiance intensity of BLI (D) pooled 
from all experiments was shown. Asterisk indicates statistical significance: *p<0.05.  
 
2.5 Discussion 
Here we show that T-bet deficient donor T cells, in contrast to IFN-γ deficient donor T 
cells, are impaired in their ability to induce acute GVHD in allogeneic recipients in fully MHC-
mismatched (Figure 2.1 and 2.6) or MHC-matched but miHA-mismatched (Figure 2.2) murine 
BMT models. We identified distinct genetic profiles of T cells deficient for T-bet or IFN-γ to 
account for this difference (Figure 2.3) and further elucidated several T-bet downstream 
molecules, independent of either endogenous or systematic IFN-γ, contributed to GVHD 
pathogenicity (Figure 2.4). Furthermore, we found that T-bet deficient donor T cells have 
preserved GVL activity when the resulting increased IL-17 is neutralized (Figure 2.9). 
Acute GVHD has been considered a Th1-type disease dominated by cytotoxic T cell-
mediated pathology and increased production of Th1-type cytokines, including IFN-γ (78, 152, 
153).  Our data indicates that T-bet is required for CD4 T-cell mediated GVHD by controlling 
the differentiation and migration of Th1 cells (Figure 2.1) and the optimal function of Th17 cells 
(Figure 2.6). T-bet-/- CD4 T cells produced significantly lower levels of the pathogenic cytokine 
TNF-α, but higher levels of the anti-inflammatory cytokine IL-10 in recipient sera after adoptive 
transfer, which lead to reduced tissue damage in the liver and gut, compared to either WT or 
IFN-γ-/- CD4 T cells (Figure 2.1). Conversely, the Th17-related cytokine IL-6 was elevated in 
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recipient sera if the donor CD4 T cells were T-bet-/- (Figure 2.1G). In addition, increased IL-17 
production by T-bet-/- donor CD4 T cells was present in recipient spleens and livers (Figure 
2.1H). Our previous study also indicates that T-bet-/- CD4 T cells produced higher levels of Th2-
related cytokines, IL-4 and IL-5, in recipient spleens, livers, and lungs (47). Consistent with 
previous reports, donor CD4 T cells can reciprocally differentiate into Th1, Th2, and Th17 cells, 
and each Th subset contributes to specific GVHD target organ tissue damage.  Liver and gut are 
the primary target organs for Th1 cells, and skin is the primary target organ for Th17 cells, 
whereas pulmonary GVHD is mainly mediated by Th17 and Th2 cells (159).  We observed that 
T-bet-/- CD4 T cells induced severe pulmonary GVHD similar to WT counterparts (Figure 2.1, E 
and F). We attribute the severe lung pathology mediated by T-bet-/- CD4 T cells to the 
augmented Th2 and Th17 cells and to the minimal IFN-γ production which leads to decrased 
PD-L1 expression on lung parenchyma (159). Moreover, due to the direct cytotoxicity of IFN-γ 
to the gastrointestinal tract (156), absence of T-bet or IFN-γ in donor CD4 T cells induced 
similar severity of colon GVHD but was less than that induced by WT CD4 T cells (Figure 2.1, 
E and F). 
Multiple preclinical studies have investigated a paradoxical protective role of IFN-γ in 
GVHD development under lethal conditioning (154-157, 287, 288). In our current settings, IFN-
γ-/- T cell induced comparable, not more severe GVHD, as their WT counterparts, which is likely 
due to the type and dose of donor T cells given was different from other studies (154-157, 287, 
288).  Taken together, the consensus is that IFN-γ produced by donor T cells is not required for 
the development of acute GVHD after lethal TBI and allo-BMT.  However, the current work 
showed that T-bet, a transcriptional activator of IFN-γ, was required for GVHD induction.  To 
further define the underlying mechanisms, we identified the differential gene profiles of donor T 
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cells deficient for T-bet or IFN-γ after allo-BMT. The potential key mediators include but are not 
limited to the following genes: Cxcr3, Ccr5, Ccl3, Ccl4, Klrc1, Klrd1, Nkg7, Pdcd1, H2-Aa and 
H2-Ab1 (Figure 2.3). These targets are either positively or negatively regulated by T-bet and 
represent different aspects of allogeneic T-cell activity: activation (H2-Aa and H2-Ab1), 
migration (Cxcr3, Ccr5, Ccl3, and Ccl4), cytotoxic function (Klrc1, Klrd1, and Nkg7) or 
exhaustion (Pdcd1).   
It is interesting that expression of MHC-II genes H2-Aa and H2-Ab1 were increased on 
T-bet-/- CD4 T cells.  The protein level of I-Ab (gene: H2-Ab1) was also significantly increased 
in T-bet-/- T cells, compared to either WT, IFN-γ-/-, or IFN-γR-/- T cells (Figure 2.4C and Table 
2.1), which we classified as a T-bet-dependent but systematic IFN-γ-independent molecule. 
Given that transfer of MHC molecules from APCs to T cells does exist, and the MHC-II-
expressing T cells can engage in T: T interactions leading to increased apoptosis and 
hyporesponsiveness (309, 310), it is possible that overexpression of MHC-II molecules (such as 
I-Ab) on T-bet-/- donor T cells may result in increased cell death due to fratricide of allogeneic T 
cells. Alternatively, those MHC-II-expressing T-bet-/- T cells may compete with professional 
dendritic cells to present antigen, but not effectively induce T-cell proliferation due to lack of 
costimulatory signals; the regulatory mechanism utilized by T-bet-NKp46-RORγt+ innate 
lymphoid cells as demonstrated in a recent report (311).  
Chemokine receptors and chemokines play important roles in T-cell migration to GVHD 
target organs (312, 313). CXCR3 is a direct target of T-bet (117), and targeting CXCR3 using its 
mAb can inhibit CD8-mediated GVHD in murine allo-BMT models (314). Targeting CCR5 
using a small molecule inhibitor (Maraviroc) has recently been reported to be beneficial in 
patients with visceral GVHD in early clinical trials (315). Additionally, gene expression of 
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CCL3 and CCL4, ligands of CCR5 (316), were also found to be positively regulated by T-bet. 
Our data further indicates that CXCR3 is likely one of the key effectors contributing to the 
severe GVHD caused by IFN-γ-/- but not T-bet-/- T cells (Figure 2.1); in that the presence of 
systematic IFN-γ preserves the high expression of CXCR3 in IFN-γ-/- T cells via IFN-γR 
signaling, which was significantly reduced in T-bet-/- T cells at the gene level (Figure 2.10). This 
was also consistent with previous reports that the addition of exogenous IFN-γ to cultures of 
IFN-γ-/- T effector cells rescued CXCR3 expression (299). Therefore, in contrast to WT or IFN-γ-
/- T cells, T-bet-/- T cells expressed significantly lower levels of Th1-related chemokine receptor 
genes (Cxcr3 and Ccr5) and chemokine genes (Ccl3 and Ccl4), as well as the CXCR3 protein. 
This impedes the migration and infiltration of allogeneic T cells to GVHD target organs (Figure 
2.1 and 2.4).  
 
 
Figure 2.10 Gene profiles of IFN-γR identified by microarray. Mean signal value ± SE of genes 
Ifngr1 and Ifngr2 identified by microarray using either WT, T-bet-/-, or IFN-γ-/- donor CD4 T 
cells 7 days post allo-BMT were shown. Pooled data from three independent experiments are 
represented. Asterisk indicates statistical significance: ***p<0.001.  
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Administration of an agonistic mAb of NKG2A inhibited donor T cell expansion and 
ameliorated acute GVHD in mice (317). However, we show that T-bet-/- donor T cells express 
extremely low levels of CD94/NKG2A genes (Klrd1and Klrc1, respectively) (Figure 2.3), and 
CD94 protein (Figure 2.4), in concert with ameliorated GVHD, suggesting that CD94/NKG2A 
could be biomarkers to positively predict GVHD severity. Lower expression levels of inhibitory 
molecules CD94, NKG2A, and T cell exhaustion marker PD-1 (Figure 2.3 and 2.4), on the other 
hand, may suggest that T-bet-/- T cells can still preserve their cytotoxic function to overcome 
tumor growth, which was additionally supported by enhanced production of GZMB by T cells 
deficient for T-bet but not IFN-γ (Figure 2.4C). Nkg7, a promoter of the T and NK cell surface 
cytotoxic molecule (318),  has been considered as a Th1 cell-specific gene of which expression 
was previously shown to be regulated by T-bet (20, 117), and is positively correlated to cytotoxic 
T-cell destruction of epidermal cells in human GVHD (319).   
In murine EAE models, deficiency in IFN-γ leads to exacerbated disease (320, 321). 
However, T-bet-deficient mice are protected from developing EAE (49, 50). We have observed 
similar results in GVHD models, which suggest that silencing Tbx21 has therapeutic potential. 
Because transcription factors are difficult to be pharmacologically targeted, an alternative 
approach is targeting T-bet downstream molecules that are independent of endogenous or 
systematic IFN-γ (Figure 2.4), such as NKG2D, which is expressed on a variety of immune cells 
and plays a costimulatory role in activating CD8 T cells (322).  Indeed, we classified NKG2D as 
a T-bet-dependent but systematic IFN-γ-independent molecule (Figure 2.4), consistent with the 
unpublished data from us and others (323), which indicates that blockade of NKG2D alleviated 
GVHD induced by CD8 or total T cells. 
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Th17 cells are capable of inducing GVHD in mice (80, 81). Both T-bet-/- and IFN-γ-/- 
CD4 T cells are prone to Th17-differentiation with high levels of IL-17 production (Figure 2.5). 
In contrast to in vitro polarized WT or IFN-γ-/- Th17 T cells, T-bet-/- Th17 cells caused very mild 
GVHD (Figure 2.6, B-E). Consistently, our microarray data reveals that T-bet controls the 
optimal function of Th17 cells in GVHD possibly through regulating the expression of multiple 
genes representing Th17 pathogenic or nonpathogenic signatures (Figure 2.7). Our study showed 
T-bet-/- and IFN-γ-/- CD4 T cells have similar expression patterns of IFN-γ and IL-17 but 
opposing GVHD severities, which indicated that the culprit for GVHD development may not be 
IFN-γ or IL-17, but likely downstream effectors of T-bet we identified. 
Although IL-17 seems to have less effect on GVHD development, it influences the tumor 
microenvironment, especially when shielding the GVL response of T-bet deficient donor T cells 
(Figure 2.9).  T-bet-/- T cells produce more IL-17 than WT T cells (Figure 2.1H and 2.5), and IL-
17 promotes tumor progression in a variety of tumors (306-308). Consistently, neutralizing IL-17 
benefits overall survival of recipients transplanted with T-bet-/-, not WT T cells.  However, the 
GVL preservation of T-bet-/- T cells is reduced after stopping anti-IL-17 treatment. The tumor 
gradually relapsed, which further supports the detrimental role of IL-17 against preserved GVL 
effects of T-bet-/- T cells.  We conclude that T-bet deficient T cells induce less GVHD and may 
still preserve GVL effects if the elevated levels of IL-17 are reversed. This is also supported by 
our previous findings that double deficiency of T-bet and RORγt prevents GVHD while sparing 
the GVL effect (47). Targeting T-bet itself is still far from translational application due to a lack 
of a specific inhibitor. Recently, the small molecule inhibitors for other transcription factors, 
such as c-Rel and RORγt, have been developed and showed promising results in alleviating 
GVHD (324) or cutaneous inflammatory disorders (325), respectively. The c-Rel inhibitor also 
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permits the maintenance of the GVL effect. Once T-bet inhibitors are developed, the mechanism 
we defined in the current study together with our previous report (47) will become applicable, 
e.g. a combinational treatment of T-bet inhibitor and anti-IL-17 mAb may be beneficial in 
controlling GVHD while maintaining the GVL effect. 
Collectively, using genetic knockout mice, we prove that T-bet is critical for the 
development of aGVHD through controlling the differentiation and migration of Th1 cells as 
well as the pathogenicity of Th17 cells. Given that T-bet is a transcription factor which is 
unavailable to be pharmacologically targeted currently, we identify potential molecular targets 
downstream of T-bet, and define the underlying mechanisms accounting for the distinct GVHD 
outcomes caused by T-bet-versus IFN-γ-deficient donor T cells. This provides the rationale to 
target those T-bet-dependent, but endogenous or systematic IFN-γ-independent molecules, for 
the control of aGVHD in clinical settings.    
In the study presented in Chapter 2, we investigated the effect and mechanism of T-bet in 
regulating T cell activity and function in the development of aGVHD after allo-BMT. 
Pharmacological blockade of T-bet, once available, is expected to affect other cell compartments 
in addition to donor T cells as far as they express T-bet.  Because APCs also express T-bet and 
play critical roles in the induction of aGVHD, we therefore studied how T-bet regulates APC 
functions in mediating aGVHD and GVL effect, and we will report our findings in the next 
chapter.   
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Chapter 3: T-bet Promotes Acute Graft-versus-Host Disease by Regulating Hematopoietic 
Antigen Presenting Cells in Mice 
 
3.1 Abstract3 
Beyond its critical role in T cells, T-bet regulates the functions of APCs including DCs 
and B cells. Given that APCs are essential for priming allogeneic T cells and the development of 
GVHD, we evaluated the role of T-bet on APCs in acute GVHD using murine models of allo-
BMT.  The recipients deficient for T-bet developed much milder GVHD than their WT 
counterparts in MHC-mismatched or CD4-depedent miHA-mismatched models. As the 
functional readout of APCs, allogeneic donor T cells, in particular CD4 subset, significantly 
reduced IFN-γ production, proliferation and migration, and caused less damage in liver and gut 
in T-bet-/- recipients. We further observed that T-bet on recipient hematopoietic APCs was 
primarily responsible for the donor T-cell response and pathogenicity in GVHD, while T-bet also 
contributes to the function of donor hematopoietic APCs.  T-bet-/- DCs, the most potent 
hematopoietic APCs, produced less IFN-γ and expressed higher levels of Trail, but not FasL or 
TNF, to induce significantly higher levels of apoptosis on donor T cells prior to their massive 
proliferation. In fact, Trail/DR5 interactions served as a major signaling pathway responsible for 
donor T-cell apoptosis and impaired GVHD development in the recipients deficient for T-bet.  
Furthermore, while T-bet on hematopoietic APCs was required for GVHD development, it was 
                                                      
3
 This abstract have been previously published (Fu et al. 56th ASH Annual Meeting, Blood, 2014, 
124 (21), 846-846.) and are utilized with permission of the publisher (p132). 
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largely dispensable for the GVL effect. Taken together with our previous findings, we propose 
that T-bet is a potential therapeutic target for the control of GVHD through regulating T cells as 
well as APCs.   
 
3.2 Introduction 
GVHD remains to be a major obstacle for the efficacy and continuing success of allo-
HSCT in the treatment of various malignant and non-malignant diseases (63). Activation of 
antigen presenting cells (APCs) plays a crucial role in priming alloreactive donor T cells to 
induce and intensify GVHD (149, 221, 239, 240). After conditioning, temporarily survived 
recipient APCs are essential for aGVHD initiation, especially in MHC-mismatched transplants 
and in CD8-mediated aGVHD across only miHAs (68).  Donor APCs also contribute to the 
increased intensity of aGVHD by priming donor T cells (239, 240), and may perpetuate cGVHD 
(238). APCs include diverse types of cells that have the common ability to prime T cells, such as 
DCs, B cells and macrophages derived from the hematopoietic system.  Hematopoietic APCs 
clearly contribute to the development of GVHD (221), although recently have been proved 
dispensable since recipient nonhematopoietic APCs, such as myofibroblasts, endothelial cells, 
and epithelial cells, are sufficient to induce lethal GVHD in mice (249, 250). Among all APCs, 
DCs are considered as the most efficacious APCs and potent inducers of GVHD due to their 
superior ability to take up antigen, express co-stimulatory molecules, and produce 
proinflammatory cytokines to polarize T cells (233, 326).  
Our group and others previously reported the fundamental role of the T-box transcription 
factor T-bet on T cells in GVHD, inflammatory diseases or autoimmune diseases (46, 47, 49, 54, 
327).  T-bet also regulates the activation and function of many APCs, such as DCs (4, 5, 58) and 
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B cells (41, 328). Although the development, differentiation and activation of bone marrow 
derived DCs and splenic DCs were unimpaired in mice lacking T-bet, T-bet is required for 
optimal production of IFN-γ and antigen-specific T-cell activation by DCs (5), which is highly 
correlated with GVHD induction. The study showed that T-bet-/- DCs failed to induce 
inflammatory arthritis due to the compromised ability to secrete proinflammatory mediators and 
to prime naive T cells (58). However, microbiome-dependent spontaneous colitis can occur in 
the absence of T-bet as a result of the derepression of TNF-α in mucosal DCs (329). Therefore, 
the effect of T-bet on DCs in the development of different diseases may depend on the 
differential microenvironment. 
In the current study, by using several well-defined, clinically relevant murine models of 
allo-BMT, we found that T-bet deficiency on hematopoietic APCs, both recipient and donor 
origin, attenuates aGVHD. The proliferation and IFN-γ production of allogeneic donor T cells 
were significantly impaired in T-bet-/- recipients, but more Foxp3+ Tregs were present in their 
spleens. Additionally, T-bet-/- APCs enhanced early apoptosis of allogeneic donor T cells within 
lymphoid organs primarily through the Trail-DR5 axis, thus contributing to their decreased 
infiltration and tissue damage to GVHD target organs. Furthermore, allogeneic donor T cells in 
T-bet-/- recipients largely preserved GVL effect. Our data demonstrate T-bet is a promising 
therapeutic target for the control of GVHD through regulating APCs functions.   
 
3.3 Materials and methods 
 
 73 
 
3.3.1 Mice 
C57BL/6 (B6; H-2b), congenic B6.Ly5.1+ (CD45.1+; H-2b), and FVB/N (FVB; H-2q) 
were purchased from National Cancer Institute. 129S2/Sv (H-2b) were purchased from Charles 
River Laboratories. T-bet-/- mice on B6 or BALB/c (H-2d) background, and C3H.SW (H-2b) 
were purchased from The Jackson Laboratory. All animals were housed in the American 
Association for Laboratory Animal Care–accredited Animal Resource Center at H. Lee Moffitt 
Cancer Center or Medical University of South Carolina (MUSC). Experiments were carried out 
under protocols approved by the Institutional Animal Care and Use Committee of University of 
South Florida or MUSC. 
 
3.3.2 BMT models 
T-cell purification from whole spleen and lymph nodes was done by negative depletion 
using magnetic beads as previously described (47). MHC- and miHA-mismatched (FVB→ B6; 
B6→BALB/c) or MHC-matched but miHA-mismatched (129S2/Sv→ B6; C3H.SW→ B6) BMT 
models were used as previously established (46, 289). Briefly, different strains of recipient mice 
were conditioned with a lethal dose of total body irradiation (TBI). Within 24 hours post-
conditioning, recipients were i.v. injected with T-cell depleted (TCD)-BM alone or plus various 
numbers of T cells purified from donor mice. Recipients were monitored for weight loss and 
other clinical signs of GVHD twice/week (163). Spleens of DR5-/- mice on B6 background and 
their wild type (WT) counterparts were kindly provided by Dr. Niklas Finnberg from Penn State 
Hershey Cancer Institute. H&E staining and a semi-quantitative scoring system were used to 
account for histologic changes consistent with GVHD in the target organs as previously 
described (46, 47, 291). 
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3.3.3 Chimeras BMT model 
WT-B6 Ly5.1+ or T-bet-/- B6 mice were lethally irradiated with 1000-1200 cGy and 
infused with TCD-BM cells from syngeneic T-bet-/- B6 or WT-B6 Ly5.1+ donors such that T-bet 
deficiency is confined to only the hematopoietic cells or the nonhematopoietic cell 
compartments, respectively. Control chimeras were also established by using lethally irradiated 
WT-B6 Ly5.1+ or the T-bet-/- B6 mice as recipients, and transferred with TCD-BM cells from 
syngeneic WT or T-bet-/- B6 donors respectively. Chimerism analyses of the donor 
hematopoietic cells were complete donor types (>95%) 2-3 months after first syngeneic BMT 
(data not shown). The [B6→ B6 Ly5.1+], [B6 T-bet-/- → B6 T-bet-/-], [B6 T-bet-/- → B6 Ly5.1+] 
and [B6 Ly5.1+ → B6 T-bet-/-] mice were then used as recipients in an allo-BMT. The chimeric 
mice received 1000-1200 cGy irradiations and were i.v. injected with purified T cells along with 
TCD-BM cells from allogeneic FVB donors.  
 
3.3.4 GVL model  
In the B6→BALB/c model, recipients received 2×103 luc/neo plasmid-transduced A20 B-
cell lymphoma cells (A20-luc) on BALB/c background, while in the FVB→B6 model, recipients 
received 0.1×106 C1498 luciferase transduced atypical myeloid leukemia cells (C1498-luc) 
generated in B6 mice at the time of BMT. Tumor mortality and GVHD mortality were 
distinguished by BLI signal intensity and clinical manifestation of GVHD (46, 291). 
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3.3.5 Flow cytometry  
Mononuclear cells were isolated from recipient spleen and liver and stained and analyzed 
for surface receptors and intracellular cytokines using standard flow cytometric protocols as 
previously described (47, 291, 292).  
 
3.3.6 In vivo mixed lymphocyte reaction (MLR) 
T cells isolated from donor mice were gently mixed and incubated with 2 μM CFSE in 
PBS at 37°C for 7 minutes. The CFSE-labeled T cells were i.v. injected into lethally irradiated 
recipients. After 4 days, recipient splenocytes were stained and analyzed using flow cytometry. 
Soluble DR5 (sDR5) protein is a human truncated DR5, which has been shown to effectively 
block Trail induced apoptosis in both human and mouse systems (330). sDR5 used in certain 
experiments was kindly provided by Dr. Youhai Chen from University of Pennsylvania. 
 
3.3.7 Statistics 
For comparison of recipient survival or tumor relapse rate, the log-rank test was used to 
determine statistical significance (p<0.05). To compare GVHD clinical scores, pathology scores, 
weight loss, cytokine levels, as well as in vivo and in vitro T-cell proliferation, a Student t test 
was used. 
 
3.4 Results 
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3.4.1 T-bet expressed on host contributes to aGVHD 
Development of GVHD is initiated by host APCs in presenting alloantigens to activate 
donor T cells (286). To determine the effect of T-bet on host APCs in vivo, we utilized a fully 
MHC-mismatched model (FVB→B6) of allo-BMT, where host APCs are essential for GVHD 
development (68). Compared to WT, T-bet-/- recipients demonstrated significantly lower 
mortality from GVHD after allo-BMT (Figure 3.1A) with less weight loss (Figure 3.1B), and 
displayed significantly better donor-derived B220+ B-cell and CD4 and CD8 T-cell 
reconstitution in spleen 80 days post-transplant (Figure 3.1, C-F). Because GVHD impairs donor  
B- and T-cell reconstitution, these results reflect that T-bet-/- recipients suffered only mild 
GVHD. The reduced mortality of T-bet-/- recipients was associated with less severe pathologic 
injuries in liver and gastrointestinal (GI) tract on day 14 post-transplant as compared with their 
WT counterparts. T-bet-/- recipients showed better maintenance of normal cell morphology in 
GVHD target organs without severe lymphocyte infiltration (Figure 3.1, G and H). Thus, T-bet 
expression in the host contributes to GVHD, suggesting a potential role of T-bet in regulating 
recipient APCs.  
3.4.2 T-bet on host determines alloresponse and impairs early apoptosis of 
allogeneic donor T cells 
APCs may affect the pathogenicity of donor T cells after allo-BMT in various ways, 
including alloreactivity, homeostasis, and/or migration. We next evaluated these aspects as the 
indirect functional readout of host APCs to understand the cellular mechanisms by which T-bet 
regulates GVHD through host APCs. Donor CD4 and CD8 T cells showed significantly reduced 
proliferation (CFSE staining) and activation (IFN-γ production) in T-bet-/- as compared to WT 
allogeneic recipients, in which more defects were observed in CD4 than CD8 T cells (Figure 3.2,  
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Figure 3.1 Absence of T-bet expression on host ameliorates GVHD.  Lethally irradiated WT or 
T-bet-/- mice on B6 background (n=9~15 per group) were transplanted with 5×106/mouse TCD-
BM from FVB donors alone, or plus purified FVB T cells at 2×106/mouse. Recipient mice were 
monitored throughout the experimental period for survival (A) and weight change (B) post-
transplant. Upon completion of the experiment on day 80, phenotypes of the spleen cells from 
survived recipients were analyzed.  Expression of H-2Kq, B220, CD4 and CD8 was detected by 
flow cytometry and absolute number of total splenocytes (C), donor-derived B cells (D), CD4 
(E) and CD8 (F) T cells were calculated. Pooled data from three separate experiments are 
presented. In separate experiments with the same setting as A-E, recipients were euthanized 14 
days post-transplant and samples of liver, lung, small intestine, large intestine, and skin were 
collected for H&E staining and scored for microscopic GVHD severity by a pathologist blinded 
to the treatment groups (G). Photomicrographs depict the average disease score morphology 
from one representative experiment (n=3~4 per group). Pathological score mean ± SE of GVHD 
target organs are depicted (H). Asterisk indicates statistical significance: *p<0.05, **p<0.01, 
***p<0.001. 
 
A-C). In those allogeneic recipients, absolute numbers of donor T cells (H-2Kq+) and CD4 T 
cells were significantly reduced in the T-bet-/- recipients compared to the WT counterparts, 
whereas the number of donor CD8 T cells were comparable (Figure 3.2 D).  The impact of T-bet 
on APCs specific to T-cell proliferation and activation was dependent on alloantigen recognition 
because such an impact on T cells was not seen in syngeneic recipients (Figure 3.3A).  We also 
noticed that apoptosis (Annexin V+) was significantly increased in CD4 and CD8 donor T cells 
in allogeneic T-bet-/- vs. WT recipients among CFSEhigh but not CFSElow population (Figure 3.2 E 
and F).  No difference in apoptosis of donor T cells was seen in syngeneic recipients regardless 
of T-bet expression (Figure 3.3B). Collectively, these data suggest that the deficiency of T-bet on 
host APCs mitigates allogeneic T-cell proliferation and IFN-γ production while enhancing 
apoptosis before they undergo massive expansion. 
 
 79 
 
 
Figure 3.2 Allogeneic donor T cells significantly reduce IFN-γ production and proliferation but 
increase early apoptosis in T-bet-/- recipients.  WT or T-bet-/- B6 mice were lethally irradiated and 
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transplanted with 3×106/mouse purified CFSE-labeled T cells from FVB donors (n=10 per 
group, pooled from three experiments). Profiles of CFSE and IFN-γ in donor CD4+ or CD8+ T 
cells were shown from representative recipients in each group 4 days post-transplant (A). 
Percentages of CFSElow (B) and CFSElow IFN-γ+ donor T cells (C) are shown, and the absolute 
numbers of total splenocytes, H-2Kq+, CD4+ or CD8+ T cells are presented (D). Profiles of CFSE 
and Annexin V in donor CD4 or CD8 T cells are shown from representative recipients in each 
group (E). Percentages of total T-cell apoptosis in CFSElow or CFSEhigh population are shown 
(F). Asterisk indicates statistical significance: *p<0.05, **p<0.01, ***p<0.001. 
 
3.4.3 T-bet expressed on host promotes donor CD4 T-cell accumulation in spleen 
and infiltration to liver 
To delineate allogeneic donor T-cell expansion and migration capacity, we utilized 
congenic marker Ly5.1 to distinguish the donor T cells (Ly5.2+) from donor BM cells (Ly5.1+). 
We found that, 7 days post-transplant, T-bet-/- recipients had higher numbers of total splenocytes, 
but significantly decreased percentage of H-2Kb+ Ly5.2+ donor T cells, resulting in the 
comparable absolute number of donor T cells in the spleens of WT and T-bet-/- recipients (Figure 
3.4 A and C). 
However, in T-bet-/- recipients, there were significantly fewer total CD4 donor T cells 
(Figure 3.4C) which also produced less IFN-γ (Figure 3.4D) or expressed lower CXCR3 (Figure 
3.4E), while recruiting significantly more CD25+Foxp3+ Tregs in the spleen compared to WT 
recipients (Figure 3.4 B and C). Moreover, fewer total and IFN-γ-producing donor CD4 T cells 
were detected in the liver of T-bet-/- recipients (Figure 3.4 G and H).  On the other hand, no 
significant differences in absolute number were observed on donor CD8 T cells in either the 
spleens or livers of T-bet-/- vs. WT recipients (Figure 3.4 C-E, G and H). Therefore, we conclude 
that increased expansion and/or generation of Tregs but decreased expansion and infiltration of 
CD4 effector T cells were likely accounted for attenuated GVHD in T-bet-/- recipients (Figure 
3.1). 
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Figure 3.3 T-bet expressed on host is dispensable for activation, proliferation, and apoptosis of 
donor T cells in syngeneic recipients.  WT or T-bet-/- B6 mice were lethally irradiated and 
transplanted with 3×106/mouse purified CFSE-labeled T cells from WT B6 donors (n= 3 per 
group). Profiles of CFSE and IFN-γ (A), and CFSE vs. Annexin V (B) in donor CD4 or CD8 T 
cells are shown from representative recipients in each group 4 days post-transplant.  
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Figure 3.4 Allogeneic donor T cells significantly decrease accumulation in spleen and 
infiltration to liver in T-bet-/- recipients. Lethally irradiated WT or T-bet-/- mice on BALB/c 
background (n=9~10 per group, pooled from two experiments) were transplanted with 
5×106/mouse TCD-BM from Ly5.1+ B6 donor alone, or plus 0.25×106/mouse purified Ly5.2+ T 
cells from B6 mice. Seven days post-transplant, mononuclear cells were isolated from recipient 
spleens and livers. Percentages of Ly5.2+ H-2Kb+ T cells (A) or CD25+Foxp3+ Tregs (B), and 
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their CD4 and CD8 subpopulation in spleen are shown. Absolute numbers of total splenocytes, 
total donor, CD4 or CD8 T cells and CD25+Foxp3+ Tregs in spleen are presented (C).  Absolute 
numbers of the donor CD4 or CD8 T cells producing IFN-γ (D) or expressing CXCR3 (E) in 
spleen are presented. Percentages (F) and absolute number (G) of liver Ly5.2+ H-2Kb+ T cells 
and their CD4 and CD8 subpopulation are shown. Absolute numbers of IFN-γ-producing donor 
CD4 or CD8 T cells in liver (H) are presented. Asterisk indicates statistical significance: 
*p<0.05, **p<0.01, ***p<0.001. 
 
3.4.4 T-bet expressed on host contributes to GVHD in CD4 but not CD8-dependent 
miHA-mismatched model 
In addition to the MHC-mismatched models, we also evaluated the effect of T-bet on 
APCs using more clinically relevant MHC-matched but miHA-mismatched models. Given 
previous findings which demonstrated that APCs derived from the host, rather than from the 
donor, are critical in inducing GVHD across miHA mismatch (218), we conditioned WT or T-
bet-/- B6 recipients by TBI and transferred purified T cells from either 129S2/Sv or C3H.SW 
donors, representing the CD4- or CD8-dependent miHA-mismatched model, respectively (123, 
218, 331). In 129S2/Sv → B6 model, WT recipients exhibited 100% lethality with severe 
clinical signs of GVHD, including weight loss, hunched posture, impaired mobility, ruffled fur, 
and skin lesions, whereas T-bet-/- recipients only showed mild GVHD with low mortality and 
morbidity (Figure 3.5 A-C). Distinct from the CD4-dependent model, in C3H.SW→ B6 model, 
no significant difference in survival, body weight change, or clinical scores was observed in WT 
versus T-bet-/- recipients (Figure 3.5 D-F). These data are consistent with those observed in 
MHC-mismatched model that T-bet on the host primarily impacts CD4 rather than CD8 donor T 
cells (Figure 3.2 and 3.4). 
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Figure 3.5 Absence of T-bet expression on host ameliorates GVHD in CD4- not CD8-depedent 
miHA-mismatched BMT model.  Lethally irradiated WT or T-bet-/- mice on B6 background (n=6 
per group) were transplanted with 5×106/mouse TCD-BM from 129S2/Sv donors alone, or plus 
purified 129S2/Sv T cells at 10×106/mouse. Recipient mice were monitored throughout the 
experimental period for survival (A), weight change (B), and GVHD clinical scores (C) post-
transplant. Data from one representative experiment are presented. Lethally irradiated WT or T-
bet-/- B6 mice (n=10~11 per group) were transplanted with 5×106/mouse TCD-BM from 
C3H.SW donors alone, or plus purified C3H.SW CD44-CD25- T cells at 3×106/mouse. Recipient 
mice were monitored throughout the experimental period for survival (D), weight change (E), 
and GVHD clinical scores (F) post-transplant. Data pooled from two independent experiments 
are presented. Asterisk indicates statistical significance between WT and T-bet-/- recipients given 
T cell transfer: *p<0.05, **p<0.01, ***p<0.001. 
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3.4.5 T-bet on host hematopoietic cells is primarily responsible for promoting 
GVHD 
Given both hematopoietic and nonhematopoietic APCs are known to contribute to the 
development of GVHD (233, 249), we next evaluated the role of T-bet expression on either 
population in mediating GVHD by using established BM chimeric mice as recipients.  Severe 
GVHD with < 20% long-term survival was induced in [B6→ B6 Ly5.1+] and [B6 Ly5.1+→ B6 
T-bet-/-] chimeras in which T-bet was intact in their hematopoietic system, whereas mild GVHD 
with > 70% long term survival was observed in  [B6 T-bet-/- → B6 T-bet-/-] and [B6 T-bet-/- → 
B6 Ly5.1+] chimeras in which T-bet was absent in their hematopoietic system (Figure 3.6). 
These results demonstrate that T-bet on recipient hematopoietic APCs plays an essential role in 
initiating GVHD, although the contribution of T-bet on nonhematopoietic APCs cannot be ruled 
out as a delayed lethality was observed in [B6 Ly5.1+→ B6 T-bet-/-] chimeras as compared to 
[B6→ B6 Ly5.1+] chimeras (Figure 3.6). 
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Figure 3.6 T-bet is critical for recipient hematopoietic APCs to induce GVHD. Lethally 
irradiated WT or four different types of chimeras ([B6→ B6 Ly5.1+], [B6 T-bet-/- → B6 T-bet-/-], 
[B6 T-bet-/- → B6 Ly5.1+] and [B6 Ly5.1+ → B6 T-bet-/-]) on B6 background (n=5~11 per 
group) were transplanted with 5×106/mouse TCD-BM alone or plus 2×106/mouse purified T 
cells from FVB donors. Recipient mice were monitored throughout the experimental period for 
survival (A) and weight change (B) post-transplant. Pooled data from two separate experiments 
are presented. Asterisk in the legend indicates statistical significance regards survival curves: 
*p<0.05, ***p<0.001.  
 
3.4.6 T-bet regulates antigen presenting ability of donor hematopoietic APCs to 
induce GVHD 
Because donor APCs also contribute to priming allogeneic T cells, we evaluated the 
effect of T-bet on donor APCs in the induction of GVHD.  To reduce the contribution of 
recipient APCs, we lethally irradiated BALB/c mice and reconstituted recipients with TCD-BM 
cells from WT or T-bet-/- B6 donors 4 days prior to transferring allogeneic T cells.  As expected, 
the recipients of TCD-BM cells alone from either WT or T-bet-/- donors survived long-term 
without GVHD.  Additional allogeneic T cells induced more severe GVHD in the recipients that 
were reconstituted with WT BM than those with T-bet-/- BM, reflected by survival, weight loss, 
and clinical scores (Figure 3.7).  These results indicate that T-bet also contributes to the antigen 
presenting ability of donor hematopoietic APCs to induce GVHD.  
 
3.4.7 T-bet-/- host DCs produce less IFN-γ and induce early apoptosis of donor T 
cells primarily through Trail/DR5 axis 
Hematopoietic APCs including DCs, B cells and macrophages that are capable of 
priming donor T cells, but host DCs rather than host B cells are critical in the induction of CD4 
or to a lesser extent CD8 T cell-dependent GVHD (243). Given T-bet does not express on 
murine macrophages (5), we thus subsequently focused on host DCs, the most potent 
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professional APCs, and intended to understand how T-bet on host DCs modulates T-cell 
responses after allo-BMT. Consistent with the previous study (5), we found that T-bet-/- DCs 
expressed similar levels of MHC-II, CD86 and CD40 on day 4 post-transplant (data not shown), 
but they produced significantly less IFN-γ compared with WT DCs during the interaction with 
allogeneic, but not syngeneic T cells (Figure 3.8A). Additionally, T-bet-/- DCs expressed higher 
levels of Trail, but not FasL or TNF-α, in allogeneic recipients (Figure 3.8B), although the 
expression level of Trail receptor DR5 on donor T cells was comparable in either WT or T-bet-/- 
recipients (Figure 3.9A). It is worth noting that CD4 T cells expressed higher levels of DR5 than 
CD8 T cells especially among CFSEhigh population in the recipients regardless of T-bet 
expression (Figure 3.9B). 
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Figure 3.7 Donor hematopoietic APCs deficient for T-bet induce attenuated GVHD. Lethally 
irradiated BALB/c mice (n=5~10 per group, pooled from two experiments) were transplanted 
with 5×106/mouse TCD-BM alone from WT or T-bet-/- B6 mice on day 0, or plus additional 
purified T cells from WT B6 mice at 1×106/mouse 3 days later. Recipient mice were monitored 
throughout the experimental period for survival (A), weight change (B) and clinical scores (C) 
post-transplant. Asterisk indicates statistical significance between WT and T-bet-/- recipients 
given T cell transfer: *p<0.05, **p<0.01, ***p<0.001. 
 
 
 
Figure 3.8 T-bet-/- host DCs induce early apoptosis of donor T cells primarily through Trail-DR5 
pathway.  WT or T-bet-/- B6 mice (n=3~4 per group, data from one representative experiment) 
were lethally irradiated and transplanted with 3×106/mouse purified CFSE-labeled T cells from 
WT B6 (syngeneic) or FVB donors (allogeneic). Production of IFN-γ (A) in host CD11c+ DCs 
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was shown from representative recipients in each group 4 days post-transplant. In allogeneic 
model, histogram of Trail, FasL and TNF-α with mean fluorescent intensity (MFI) are shown (B) 
on gated CD11c+ cells. WT or T-bet-/- B6 mice (n=3 per group) were lethally irradiated and 
transplanted with 3×106/mouse purified CFSE-labeled T cells from FVB donors. Recipients were 
i.p. injected with either PBS control or sDR5 at 100µg/mouse on day 0, and 50µg/mouse on day 
1, 2, and 3. Four days post-transplant, absolute numbers (C) of total donor CD4 or CD8 T cells 
and percentage (D) of AnnexinV+ T cells in CFSEhigh or CFSElow population in spleen were 
shown.  Lethally irradiated WT or T-bet-/- BALB/c mice (n=5~6 per group) were transplanted 
with 5×106/mouse TCD-BM from WT B6 donor alone, or plus 1×106/mouse purified WT or 
DR5-/- T cells on B6 background. Recipient mice were monitored throughout the experimental 
period for survival (E), and clinical scores (F) post-transplant. Asterisk indicates statistical 
significance: *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.9 DR5 expression on donor T cells in WT or T-bet-/- allogeneic recipients. WT or T-
bet-/- B6 mice were lethally irradiated and transplanted with 3×106/mouse purified CFSE-labeled 
T cells from FVB donors (n= 3 per group). Four days post-transplant, recipient spleens were 
harvested and stained for flow cytometry analysis. Histograms of DR5 expression on donor CD4 
or CD8 T cells (A), and on CFSEhigh or CFSElow donor T cells (B) are shown from representative 
WT or T-bet-/- recipients in each group.  
 
To test whether Trail/DR5 interaction was responsible for the induction of donor T-cell 
apoptosis (Figure 3.2 E and F) and subsequent reduction of GVHD (Figure 3.1) in T-bet-/- 
recipients, we utilized two strategies: blocking Trail/DR5 interaction using sDR5 or using T cells 
from DR5-/- donors. While donor T cells exhibited lower levels of expansion and higher levels of 
apoptosis in CFSEhigh population in T-bet-/- recipients, the treatment with sDR5 largely 
compensated the difference in the absence of T-bet (Figure 3.8 C and D), suggesting that 
Trail/DR5 axis contributed to the impaired donor T-cell proliferation and increased early 
apoptosis in T-bet-/- recipients. Using DR5-/- mice as donors, we observed that T cells 
proliferated slightly faster in the absence of DR5 in vitro (Figure 3.10), but had a comparable 
ability to induce GVHD in WT recipients in vivo (Figure 3.8 E and F). While WT T cells 
induced severe GVHD in WT recipients, they failed to do in T-bet-/- recipients, reflected by the 
overall survival (Figure 3.8E) and GVHD clinical scores (Figure 3.8F). Concersely, DR5-/- donor 
T cells were able to induce severe GVHD in the recipients regardless of T-bet expression (Figure 
3.8 E and F).  These data strongly suggest that the Trail/DR5 interaction is a major signaling 
pathway responsible for donor T-cell apoptosis induced by T-bet-/- APCs, through which the 
development of GVHD is alleviated.   
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Figure 3.10 Ex vivo MLR profile of WT or DR5-/- T cells. Purified WT or DR5-/- splenic T cells 
on B6 background were labeled with CFSE, and mixed with CD11chigh splenic DCs from FVB 
donor at the ratio of 10:1 (T: DC) in a 96-well plate. Five days later, mixed cells were stimulated 
with PMA plus Inomycin and harvested for flow cytometry analysis. Profiles of CFSE and IFN-γ 
in donor CD4 or CD8 T cells were shown from representative wells in each group. 
 
3.4.8 T-bet-/- recipients partially maintain GVL effect 
We next evaluated whether T-bet-/- hosts may preserve the T-cell mediated GVL effect.  
Using A20 B-cell lymphoma with a relatively low dose of T cells, we observed that while donor 
T cells induced less severe GVHD in T-bet-/- recipients (Figure 3.11A) as presented above 
(Figure 3.1), they mediated a robust GVL effect in either WT or T-bet-/- recipients (Figure 3.11B, 
p>0.05).  It is notable that the T-bet-/- recipients had delayed lymphoma relapse although 
somewhat higher rate in the later stage (Figure 3.11B). Using C1498 atypical myeloid leukemia 
with a relatively high dose of T cells, we found that T-bet-/- recipients had significantly better 
survival than WT recipients (Figure 3.11C), and most of T-bet-/- recipients were free from 
leukemia relapse (Figure 3.11D).  In fact, leukemia relapse in those recipients did not occur until 
more than 70 days after BMT (Figure 3.11 D and E). Taken together, T-bet expression on the 
host is critical for GVHD induction but much less important for mediating the GVL effect.  We 
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further observed that donor CD8 T cells expressed comparable levels of CD107a and granzyme 
B in T-bet-/- recipients compared with WT recipients (Figure 3.12), which likely contributed to 
preserved GVL activity.  
 
 
Figure 3.11 T-bet-/- recipients partially preserve GVL effect. WT or T-bet-/- BALB/c mice 
(n=11~13 per group) were lethally irradiated and transplanted with 5×106/mouse TCD-BM from 
WT B6 donors alone, or plus purified T cells from WT B6 donors at 0.25×106/mouse. 
Additionally, recipients were i.v. injected with 2×103 A20-luc on BALB/c background at the 
time of BMT. Recipients were monitored throughout the experimental period for survival (A), 
and tumor growth by luciferin i.p. injection and whole-body BLI. Percentages of tumor relapse 
are shown (B). Data pooled from two separate experiments. WT or T-bet-/- B6 mice (n=7~8 per 
group) were lethally irradiated and transplanted with 5×106/mouse TCD-BM from FVB B6 
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donors alone, or plus 2×106/mouse purified T cells from FVB donors. Additionally, recipients 
were i.v. injected with 1×105 C1498-luc generated in B6 mice at the time of BMT. Recipients 
were monitored throughout the experimental period for survival (C), and tumor growth. 
Percentages of relapse (D) and recipient BLI image (E) are shown. Tumor mortality and GVHD 
mortality were distinguished by BLI signal intensity and clinical manifestation of GVHD. 
Asterisk indicates statistical significance between WT and T-bet-/- recipients given T cell 
transfer: *p<0.05, **p<0.01, ***p<0.001. 
 
 
 
Figure 3.12 T-bet on host is not required for CD107a and granzyme B production by donor CD8 
T cells. Lethally irradiated WT or T-bet-/-  mice on BALB/c background (n=4~10 per group, 
pooled from two experiments) were transplanted with 5×106/mouse TCD-BM from Ly5.1+ B6 
donor alone, or plus 0.25×106/mouse purified Ly5.2+ T cells from B6 mice. Seven days post-
transplant, mononuclear cells were isolated from recipient spleens and stained for flow 
cytometry analysis. Percentage of donor CD8 T cell producing granzyme B and expressing 
CD107a was shown on gated Ly5.2+ H-2Kb+ CD8+ cells in spleen from representative recipients 
in each group.  
 
3.5 Discussion 
As the predominant sensors of GVHD initiation, APCs become an attractive target for 
GVHD control. After conditioning, residual host hematopoietic APCs, nonhematopoietic APCs, 
and donor APCs transferred with the allograft are all capable to prime allogeneic donor T cells 
and contribute to GVH reactions (221, 239, 249, 250). Our data demonstrate that T-bet is critical 
 94 
 
for the activity and function of hematopoietic APCs on both host and donor origin to induce 
GVHD in MHC-mismatched models (Figure 3.1, 3.6 and 3.7), through regulating donor T-cell 
alloresponse (Figure 3.2 A-D), apoptosis (Figure 3.2 E and F), and migration (Figure 3.4).  T-bet 
on the host also boosts GVHD mediated by CD4 but not by CD8 T cells in miHA-mismatched 
BMT model. We further validate that T-bet on hematopoietic APCs, particularly DCs, promotes 
allogeneic T-cell response by limiting apoptosis through down-regulating Trail expression 
(Figure 3.8).  
Either hematopoietic or nonhematopoietic APCs in the recipient are capable of activating 
donor T cells and inducing GVHD (219, 221, 249, 250, 261). Our chimeras BMT data 
demonstrate that deficiency of T-bet, particularly on host hematopoietic APCs, to a much lesser 
extent on nonhematopoietic APCs, attenuated the severity of GVHD (Figure 3.6). DCs are 
considered as the most efficacious hematopoietic APCs in T-cell priming and GVHD induction 
(68, 243). T-bet has been shown to regulate optimal production of IFN-γ and antigen-specific T-
cell activation by DCs (5). Consistently, we also observed impaired IFN-γ production by T-bet-/- 
CD11c+ DCs in the allogeneic but not syngeneic recipients (Figure 3.8A) associated with 
compromised allogeneic T-cell activation and proliferation (Figure 3.2), suggesting that T-bet 
positively regulates allo-stimulatory functions of DCs.  
It is clear that T-cell proliferation, activation and apoptosis in syngeneic recipients were 
intact regardless of T-bet expression (Figure 3.3), indicating that T-bet expression on host APCs 
does not impact T-cell homeostatic response. In allogeneic BMT, recipient APCs present 
alloantigens directly to activate donor T cells, which are essential for GVHD development (68). 
The fact that T-bet-/- recipients developed only mild GVHD (Figure 3.1) suggests the essential 
role of T-bet in regulating activity of recipient APCs. The first several days post-transplant are 
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considered to be critical in GVHD induction according to the studies of spatial and temporal 
dynamics of alloreactive T cell activation, proliferation, and tissue distribution (332, 333),  and 
the most actively dividing T cells are specific for recipient alloantigens in this period of time 
(334, 335). Thus, the CFSElow population has been referred as fast-dividing alloreactive T cells, 
and CFSEhigh population as slow-dividing non-alloreactive T cells (336, 337). In MHC-
mismatched BMT (Figure 3.2), the frequency of alloreactive T cells among total donor T cells 
should the same in WT or T-bet-/- recipients at the time of transplant. A large proportion of 
CFSEhigh T cells undergoing apoptosis in T-bet-/- recipients was likely a dynamic event, in which 
alloreactive T cells died before they would be able to further expand.  Given T-bet on the host 
did not affect T-cell homeostatic response, we surmise that those T cells undergoing apoptosis 
trigged by T-bet-/- APCs were alloreactive T cells. Interestingly, the percentages of apoptosis 
were comparable among CFSElow T cells in WT or T-bet-/- recipients (Figure 3.2 E and F).  It is 
possible that those fast dividing CFSElow T cells were undergoing activation-induced cell death 
(AICD) through FasL/Fas pathway (338), and the slow-dividing CFSEhigh T cells were instead 
sensitive to Trail/DR5-mediated apoptosis as discussed below.  Evaluation of the expression of T 
cell activation markers, including CD25, CD44, CD69, CD122, and phos-ZAP70, as well as the 
cell cycle analysis in CFSEhigh population, would be helpful to further understand the apoptosis 
mechanisms. 
The apoptosis of donor T cells after allo-BMT appears to be an important process in 
regulating T cell homeostasis (339, 340). T-cell apoptosis generally occurrs through two 
pathways termed active apoptosis, mediated by death receptor signaling (341, 342), and passive 
apoptosis, controlled by bcl-2 family members (343). Active apoptosis has been shown to be one 
mechanism to limit the survival of both alloreactive and bystander donor T cells in GVHD (338). 
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Death receptors including Fas, TNFR, and DR5, are cell surface receptors that transmit apoptotic 
signals initiated by specific TNF family ligands such as FasL, TNF-α and Trail, respectively 
(342). Our data shows that T-bet-/- CD11c+ DCs upregulated Trail, but not FasL or TNF-α 
expression (Figure 3.8B), to induce allogeneic T cell apoptosis. Signal blockade by sDR5 
treatment or using donor T-cell deficient for DR5 (Figure 3.8) further proved our hypothesis that, 
the Trail/DR5 axis plays an important role for the alleviated GVHD in T-bet-/- hosts. Our data is 
in line with a previous study, which showed that genetically modified Trail-transduced DCs 
protected mice from GVHD and leukemia relapse through inducing of apoptosis of both 
alloreactive T cells and tumor cells (285).  
T-cell migration to GVHD target organs is required for GVHD development.  We found 
less infiltrated donor CD4 but not CD8 T cells in the livers of T-bet-/- recipiets (Figure 3.4), 
which is likely due to the significantly decreased accumulation of CXCR3+ CD4 T cells in the 
spleens of those recipients, given the interaction of chemokine and chemokine receptors plays an 
important role in mediating T-cell migration to GVHD target organs (312, 313). Previous studies 
showed that CD4 and CD8 T cells have distinct characteristics and functions beyond MHC 
restriction, where CD8 T cells have survival advantages and lower sensitivity towards apoptosis 
than CD4 T cells (344). Indeed, we noticed that, CD8 T cells expressed lower levels of DR5 than 
CD4 T cells, particularly in CFSEhigh population, in either WT or T-bet-/- allogeneic recipients 
(Figure 3.9B). Not only in apoptosis, but also in activation, proliferation, and migration, CD4 T 
cells seemed always to be more sensitive than CD8 T cells on those defects upon interacting with 
T-bet-/- APCs in MHC-mismatched BMT (Figure 3.2 and 3.4). These results are further 
supported in MHC-matched BMT, where T-bet expression on hosts contributes to the 
development of GVHD induced by CD4 but not CD8 T cells (Figure 3.5). A reduced effect of T-
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bet-/- APCs on CD8 T cells may account for the preserved GVL effect (Figure 3.11).  More 
specifically, we found that CD8 T cells maintained their cytolytic function reflected by preserved 
CD107a and granzyme B expression (Figure 3.12).   
In conclusion, we demonstrated that T-bet up-regulates IFN-γ production and down-
regulates Trail expression on recipient DCs, which promotes donor T-cell activation and 
mitigates T-cell apoptosis, respectively. T-bet plays a critical role in the development of GVHD 
by regulating the activity of hematopoietic APCs, particularly DCs. Taken together with our 
recently published findings, we propose that T-bet is a potential therapeutic target for the control 
of GVHD through regulating T-cell activation and differentiation as well as APC functions (46).  
Although currently unavailable, a small molecular inhibitor to T-bet can be developed, given 
other inhibitors to RORγt or c-Rel have been generated as therapeutic intervention in 
autoimmunity and transplantation (324, 325). Alternatively, T-bet may be silenced with siRNA 
or shRNA strategy as gene-based therapy (345).  We are therefore optimistic that our findings 
will be translated into the clinic in the near future to benefit patients for controlling GVHD and 
leukemia relapse after allo-HSCT.  
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Chapter 4: Conclusions and Future Directions 
 
Our study provides insightful mechanisms and proves the concept that targeting T-bet can 
largely prevent aGVHD by regulating the functions of both T cells (46) and APCs (48). Previous 
investigations of T-bet had mainly focused on its most well-known target IFN-γ. However, 
accumulating evidence indicates the existence of T-bet-dependent but IFN-γ-independent 
components accounting for the pathogenesis of aGVHD, as well as autoimmune diseases 
including EAE (6). The novelty of current study is that, we uncovered for the first time T-bet can 
regulate T cell function in an IFN-γ-independent manner. At gene and protein levels, we 
identified the molecules that uniquely regulated by T-bet are potentially critical for GVHD 
development, and thus may serve as valid targets for the control of GVHD after allo-BMT, 
which permits alternative therapeutic strategy rather than directly targeting T-bet given the 
transcription factor is generally difficult to be targeted pharmacologically.  The novelty of our 
current work also lies in the negative regulation of Trail expression on host DCs by T-bet after 
allo-BMT, through which T-bet on DCs protects allogeneic T cells from apoptosis.   Altogether, 
we found that T-bet positively regulates activation and function of both T cells and DCs, which 
sets a strong rationale to pharmacologically inhibit T-bet for the control of GVHD through both 
T cells and APCs synchronously. 
Further studies are required to address remaining unsolved questions and translate our 
findings towards clinic application. The gene-based therapy (345) using siRNA or shRNA to 
silence T-bet could be a direct targeting strategy due to the lack of small molecular inhibitor 
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specific for T-bet. Mice transferred with siRNA-T-bet transfected splenocytes failed to develop 
EAE (49), and administration of siRNA-T-bet has been suggested could effectively alleviate 
established EAE in mice (346).  Our pilot experiments indicate that a single dose of siRNA-T-bet 
(50µg/mouse) on the day of BMT failed to significantly ameliorate the overall GVHD severity 
(unpublished observation).  Thus, the optimal dose and treatment period of siRNA-T-bet as a 
prophylaxis under allo-BMT settings will require further investigation.  
Transcription factors generally working in pairs by forming the complex and generating 
chromatin modifications that associated with gene activation or repression. Same is true for T-bet 
to perform its translational regulation on T cell differentiation (2, 347). T-bet recruits JMJD3 (a 
histone H3K27 demethylase) and SET7/9 (a histone H3K4 methyltransferase) to transactivate 
Ifng gene and promote Th1 differentiation. This process is further enhanced by HLX and 
RUNX3, the transcription factors encoded by T-bet target genes Hlx and Runx3. T-bet binds to 
RUNX3 to silence Il4 gene and it also prevents the GATA3-mediated activation of Th2-related 
cytokine genes Il4, Il5 and Il13by binding to GATA3. Similarly, T-bet interacts with RUNX1 to 
suppress Th17 differentiation, and recruits BCL6 to block Tfh lineage commitment. These 
enzymes or transcription factors form complex with T-bet could also be the potential target for 
the prevention of aGVHD. For example, JMJD3 has recently been suggested a critical role in 
regulating CD4 T-cell differentiation in a Th1-dependent colitis model. Deficiency of JMJD3 
inhibits Th1 differentiation while promoting Th2 and Th17 generation (348). The small molecule 
inhibitor GSK-J1 that is selective for the JMJ subfamily (JMJD3 and UTX) is currently available 
(349, 350). Inhibitors for SET7/9 were identified by the high-throughput screening (351), 
although the effect of SET7/9 in the development of GVHD has not been tested.  
 100 
 
Alternatively, indirectly targeting downstream effectors of T-bet on T cells, such as those 
T-bet-dependent but IFN-γ-independent molecules (e.g. CXCR3, NKG2D) we identified, is 
presumably providing a beneficial outcome, as suggested by others (314, 323) and our 
unpublished work. Our preliminary data indicate that, blocking NKG2D using its mAb could 
effectively attenuate aGVHD in mice. One limitation is the lack of proven of those genes we 
identified are unique target genes directly controlled by T-bet, which could be defined and 
confirmed by using the chromatin immunoprecipitation (ChIP) assays.  On the aspect of APCs, 
genetically modified DCs (e.g. over-expressing Trail) may be effective to combat aGVHD by 
inducing alloreactive T cell apoptosis while preventing leukemia relapse (285). This is in line 
with our observation in allo-BMT settings, where T-bet upregulates Trail in DCs and prevents 
the early apoptosis of allogeneic donor T cells, although we have not determined whether the 
deficiency of T-bet in DCs also induce the apoptosis of tumor cells. 
Another option is to modify upstream regulators of T-bet. MicroRNAs (miRs) have the 
potential for novel therapeutics in GVHD (352, 353), as suggested by different studies done by 
us and others. MiR-17-92 (354), miR-155(355), miR-34a (356), miR-100 (357), and miR-142 
(358) have all been implicated a significant role in GVHD. Further investigation on miR-29 to 
regulate GVHD is attractive due to inhibition of IFN-γ production by repressing both T-bet and 
Eomes (22). Moreover, recent studies suggest that, T-bet could be regulated by the histone 
metyltransferase Ezh2, at both transcriptional and posttranslational levels (359). Ezh2 can 
directly activate Tbx21 transcription by binding to its promoter in Th1 cells, while Ezh2 is also 
required to protect T-bet degradation mediated by proteasome. Follow-up study showed that 
conditional loss of Ezh2 in donor T cells could attenuate GVHD while still preserve the GVL 
effect after allo-BMT (360). The tyrosine kinase c-Abl has been reported to catalyze the tyrosine 
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phosphorylation of T-bet DNA-binding domain and therefore enhance the transcriptional 
activation of T-bet and Th1 differentiation (361). Combinational inhibition of c-Abl and PDGF 
receptors using imatinib or nilotinib could protect against murine sclerodermatous cGVHD 
(362). The intervention of c-Abl in the prevention or treatment of aGVHD has not yet been 
evaluated.  
Taken together, by using the genetically knockout mice, we have proved that targeting T-
bet can prevent aGVHD and leukemia relapse, with additional IL-17 neutralizing Ab treatment 
when necessary.  The next step is to achieve the translational application. As discussed above, it 
is challenging but promising to develop the therapeutic strategies to target T-bet or its related 
pathways to control GVHD and prevent leukemia relapse after allo-HSCT. 
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